



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/78, 14/435, 7/06, A61K 38/17, A61P 25/28</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/18801</b> <b>(43) International Publication Date:</b> 6 April 2000 (06.04.00)
<b>(21) International Application Number:</b> PCT/DK99/00500 <b>(22) International Filing Date:</b> 23 September 1999 (23.09.99) <b>(30) Priority Data:</b> PA 1998 01232 29 September 1998 (29.09.98) DK PA 1998 00592 29 April 1999 (29.04.99) DK <b>(71)(72) Applicants and Inventors:</b> RØNN, Lars, Christian, B. [DK/DK]; Rektorparken 14, 3.th., DK-2450 København SV (DK); BOCK, Elisabeth [DK/DK]; Tonysvej 20, DK-2920 Charlottenlund (DK); HOLM, Arne [DK/DK]; Skodsborgparken 20, 2.tv., DK-2942 Skodsborg (DK); OLSEN, Marianne [DK/DK]; Mosevej 5, DK-4000 Roskilde (DK); ØSTERGAARD, Søren [DK/DK]; Borrebyvej 21, DK-2700 Brønshøj (DK); JENSEN, Peter, H. [DK/DK]; Ahlefeldtsgade 18A, 1.th., DK-1359 København (DK); POULSEN, Flemming, M. [DK/DK]; C.F. Richsvej 99A, 1.tv., DK-2000 Frederiksberg (DK); SOROKA, Vladislav [UA/DK]; Tuborgvej 58, 1.tv., DK-2900 Hellerup (DK); RALETS, Igor [UA/DK]; Nørre Allé 8, 111, DK-2200 København N (DK); BEREZIN, Vladimir [UA/DK]; Nørrebrogade 223, 1.th., DK-2200 København N (DK). <b>(74) Agent:</b> PATRADE A/S; Aaboulevarden 21, DK-8000 Aarhus C (DK).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> NCAM BINDING COMPOUNDS		
<b>(57) Abstract</b>  The invention provides novel compounds which are capable to stimulate the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to pharmaceutical compositions, medicaments and methods for treatment of normal, degenerated and damaged NCAM presenting cells.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## NCAM BINDING COMPOUNDS

The present invention relates to treatment of diseases and conditions of the central and peripheral nervous system, treatment of diseases and conditions of muscles and treatment of diseases and conditions of various organs. In particular, the present invention concerns new compounds which are capable of stimulating proliferation of and/or neurite outgrowth from cells presenting the neural cell adhesion molecule (NCAM), such as neurones. In a further aspect, the present invention relates to compositions, and medicaments as well as methods for treating normal, degenerated or damaged NCAM presenting cells.

15

## BACKGROUND OF THE INVENTION

The brain and thus nerve cells and their function have during the last decades become an increasing subject of scientific investigations. Without doubt, the proper function of this complex system is extremely important for the proper function of the body and mind. It has been found that physical and mental malfunction can be related to i.a. abnormalities in level of signalling compounds, including neurotransmitters. Some malfunctions can be related to decay of nerve cells (neurones), connections between nerve cells and connections between muscle cells and nerve cells. This is e.g. the case in neurodegenerative diseases such as Alzheimer's Disease, where death of nerve cells leads to senility.

30

During the development of the brain, connections between nerve cells (neurones) are formed. Such connections are necessary for communication between neurones to occur, allowing individual neurones to function together as a whole. In the mature brain, connections between neurones

35

are constantly remodulated to accommodate new demands from a changing environment. The ability to remodulate neural connections is crucial in learning and memory and in regeneration, e.g. after damage to the brain or in  
5 neurodegenerative diseases.

It is believed that the mechanisms controlling the formations of neural contacts are generally similar in the developing and the mature. Several mechanisms are  
10 involved in the formation of contacts between neurones including cell adhesion, the formation of nerve cell extensions (neurites), fasciculation (bundling of individual neurites) and formation of contact points (synapses).

15

Cell adhesion molecules (CAMs) constitute a group of proteins mediating adhesion between cells. A major group of CAMs belongs to the immunoglobulin (Ig) superfamily characterised by the presence of immunoglobulin domains.  
20 The neural cell adhesion molecule (NCAM) is such a cell adhesion molecule of the Ig superfamily that is particularly abundant in the nervous system. NCAM is expressed in the outer membrane of nerve cells. When one NCAM molecule binds to another NCAM molecule on another  
25 cell, the binding between the two cells is strengthened. NCAM not only binds to NCAM but also to other proteins found on nerve cells or in the extracellular substance of the brain (the extracellular matrix). By mediating adhesion between nerve cells - or between nerve cells and  
30 the extracellular matrix - NCAM influences migration of cells, extension of neurites, fasciculation of neurites and formation of synapses.

NCAM expression is correlated with morphogenic events  
35 suggesting that NCAM is important during development (Edelman 90). Thus, NCAM is believed to be important for



the development of the nervous system (Daston et al 1996) and various organs including the kidney (Lackie et al 1990), the liver (Knittel et al 1996), the bowel (Romanska et al 1996), the heart (Gaardsvoll et al 1993),  
5 the gonads (Møller et al 1991), the pancreas (Møller et al 1992), and the muscles (Landmesser et al 1990). Therefore, ligands capable of influencing NCAM function may potentially be beneficial in conditions of impaired development of these organs by inducing appropriate  
10 differentiation of target cells (Walsh et al 1990). In the brain, the role of NCAM has been supported by knock out mice which have altered development of certain brain regions, including the olfactory system, the hippocampus, the cerebellum and the retina (Cremer et al 1994). In  
15 these tissues, the lack of NCAM expression impairs migration of cells (Ono et al 1994) and outgrowth and fasciculation of neurites (Cremer et al 1997) which in turn leads to altered synaptogenesis and morphological and functional changes. Transgenic mice with a change in  
20 the NCAM gene to produce only soluble NCAM forms die before birth further indicating that NCAM functions have great potential to interfere with development (Rabinowitz et al 1996).

25 In the mature nervous system, NCAM have been shown to be important for the plasticity of neuronal connections associated with regeneration, learning and memory (Fields et al 1996). In the peripheral nervous system, NCAM is believed to be necessary for outgrowth of nerve fibres  
30 and formation of nerve-muscle connections in regeneration after damage including lesions (Nieke et al 1985) and stroke (Jucker et al 1995).

Moreover, NCAM is presumably involved in ageing-related  
35 impairments in the ability to regenerate peripheral nerves and nerve-muscle connections (Olsen et al 1995) as

well as in a number of degenerative muscle diseases (Walsh et al 1985). A similar role of NCAM has been observed in the central nervous system where NCAM is believed to be important for neuritic outgrowth, fasciculation, branching and probably target recognition associated with regeneration (Daniloff et al 1986). In addition, NCAM-MAG double knock out mice have shown that NCAM is also necessary for myelination of neuronal fibres which is of crucial importance for neuronal function (Carenini et al 1997). In learning, subtle remodelling of neuronal connections is necessary for the stabilisation of a memory trace and it has been shown that NCAM expression changes concomitant with such changes (Doyle et al 1992). Moreover, interference with NCAM function by antibodies or in knock out mice impairs the ability to learn (Luthi et al., 1994; Rønn et al., 1995; Scholey et al 1993). From knock out mice, it has become evident that NCAM is also involved in other behavioural phenomena. Thus, NCAM knock out mice have altered circadian rhythm (Shen et al 1997) and males shown increased aggression (Stork et al 1997). In humans, elevated levels of soluble NCAM forms have been shown in schizophrenia (van Kammen et al 1998) and sclerosis (Massaro et al 1987) suggesting that NCAM could be of importance for these diseases.

NCAM is found in three main forms of which two are transmembrane forms while the third form is attached to the membrane by a lipid anchor (see FIGURE 1). All three forms have the same structure extracellularly consisting of five immunoglobulin domains (Ig domains) and two fibronectin like domains (FnIII domains). A precursor form of the NCAM contains a signal sequence. The amino acid sequence of 140 Kd isoform precursor of human NCAM is shown in Figure 17. The Ig domains are numbered one to five from the N-terminal, that is Ig1 to Ig5. The fibronectin domains are likewise called FnIII1 and

FnIII2. In addition to mediating cell adhesion, NCAM affect signal transduction in cells (Schuch et al 1989). When an NCAM molecule at the cell surface binds to another cell, a signal is transmitted to the interior of the cell (transmembrane signalling). Within the cell, a signalling cascade is activated that subsequently influences the behaviour of the cell. It has been shown that signalling initiated by NCAM binding can stimulate neurite extension (Doherty et al., 1996).

10

It is unclear, which of the NCAM domains mediate cell adhesion and signal transduction. The generally accepted hypothesis predicts that homophilic NCAM adhesion is mediated by a transreciprocal interaction between the Ig3 domains of two opposing NCAM molecules. Considerable evidence supports this notion and a putative binding site has been identified (Rao et al 1992, Rao et al 1994, Sandig et al 1994). Also ligands affecting the Ig3 domain have been shown to inhibit NCAM mediated cell adhesion. A recent hypothesis predicts that not only the Ig3 but all five Ig-domains mediate homophilic NCAM binding (Ranheim 96). According to this hypothesis, Ig1 of one NCAM molecule binds to Ig5 of another NCAM molecule, Ig2 binds Ig4 and Ig3 binds to Ig3. Thus these two theories of NCAM binding are partially overlapping. The present inventors and their colleagues have recently proposed that a double reciprocal interaction between Ig1 and Ig2 domains of two opposing NCAM molecules may mediate homophilic NCAM binding (Thomsen et al. (1996), Kiselyov et al. (1997), Rønn (1997). Rønn observed an inhibition of aggregation of neurones in a culture of hippocampal cells when adding small peptides which were previously identified as capable of binding to the NCAM Ig1 domain. An additional stimulation of neurite outgrowth was also seen. Rønn neither disclosed the sequence of the peptides studies nor suggested an exploitation of his observations in

35

medical treatment. In conclusion, the mechanism of homophilic NCAM binding is still a matter of debate although most researchers in the field favour the hypothesis of a an reciprocal interaction between all  
5 five Ig domains or at least between the Ig3 domains of two opposing NCAM molecules.

Antibodies against NCAM, purified NCAM protein and recombinant NCAM domains have been shown to induce signal  
10 transduction in certain cells. High concentrations of NCAM antibody can induce a transient calcium increase as well as a pH change in some but not all neuronal cells (Schuch et al 1989). The recombinant NCAM domains Ig1 and Ig2 and the combined domains Ig1-5 can induce a similar  
15 transient calcium increase and change in pH in certain cells (Frei et al 1992). When used as a substrate or expressed by a monolayer of cells, the NCAM protein can stimulate neurite extension. The response depends on an interaction between the FnIII domains of NCAM with  
20 fibroblast growth factor (FGF)-receptors (Doherty et al 1996). In addition, an interaction between the cytoplasmic part of NCAM with the tyrosine kinase fyn is of importance for neurite outgrowth (Beggs et al 1997).

25 This interaction is believed to activate the Ras-MAP-Kinase pathway (Schmid, R-S et al 1999).

Also, recombinant NCAM domains immobilised to the substratum can stimulate neurite extension, branching of  
30 neurites or fasciculation of neurites. Thus the FnIII domains of NCAM can increase branching of neurites when used as a substratum (Stahlhut et al 1997, Kasper et al 1996). Moreover, the FnIII domains have been reported to be the most potent NCAM domains to influence cell  
35 spreading and neurite outgrowth. Ig 1-5 also influenced these processes but less potently than the FnIII domains

(Frei et al 1992). In contrast, Ig1 and Ig2 most potently promoted cell adhesion and cell migration in this study (Frei et al 1992). Frei et al also observed stimulation of neurite outgrowth by the isolated NCAM domains Ig3, Ig4, Ig5, FnIII,1 and FnIII,2, but not by Ig1 and Ig2. A sequence located between the Ig5 and the FnIII,1 domains have been shown to be important for fasciculation of neurites (Pollerberg et al 1993). The Ig5 domain of NCAM is of major importance for neurite outgrowth due to the presence or absence of the sugar chains polysialic acid (PSA) on this domain (Rutishauser et al 1996). Likewise, the Ig4 domain is important due to the presence or absence of the alternatively spliced domain VASE (Doherty et al 1992). Synthetic peptides corresponding to the VASE sequence have been shown to interfere with NCAM stimulated neurite outgrowth (Lahrtz et al 1997). Moreover, the NCAM Ig4 domain is presumed to bind another cell adhesion molecule, L1, and thereby to influence neurite outgrowth (Horstkorte et al 1993). In contrast to the effect of immobilised reagents, NCAM antibodies or recombinant domains inhibit neurite outgrowth when added in solution. Peptides corresponding to the presumed homophilic binding site in Ig3 or mutations in this sequence in the Ig3 domain have been shown to inhibit neurite outgrowth stimulated by NCAM (Sandig et al 1994).

However, an antibody against NCAM has recently been shown to stimulate neurite outgrowth (US patent no. 5667978). This antibody recognises the Ig3 domain of NCAM. All NCAM domains have moreover been shown to influence proliferation of glial cells, neuroblastoma cells and fibroblasts, the Ig3 domain being the most potent. This function has been shown to require interaction with MAP kinase activity (Krushel 1998). It has been shown that various inhibitory ligands of the NCAM Ig3 domain, including small peptides corresponding to parts of the

Ig3 domain sequence, can inhibit glial proliferation (WO 96/18103).

5 These data suggest, that the NCAM protein or NCAM ligands could potentially influence functions of the nervous system and other tissues. Inhibiting glial proliferation would potentially be beneficial in degenerative conditions (WO 96/18103, US 5 625 040, US 5 667 978). Alternatively, if NCAM functions, particularly the  
10 induction of neurite outgrowth, could be stimulated, a beneficial effect on brain function would be possible. A stimulation of certain in vitro NCAM functions has been described for an antibody against NCAM Ig3 (US 5 667 978). However, no small ligands of NCAM with significant  
15 stimulatory effect on NCAM functions has been described. Moreover, it is not evident to which NCAM domain such a ligand should be targeted. Most evidence points at the NCAM Ig3 domain as the crucial domain for homophilic binding while the cytoplasmic part of NCAM together with  
20 the FnIII domains are presumed to be most important for interactions with signalling molecules.

In the Ph.D. thesis "NCAM and Neural Plasticity" (Rønn 1997), the role of NCAM in neural plasticity was studied.  
25 Different assays (test systems), including aggregation of neural cells, neurite extension and long-term potentiation (LTP) were used to study how the role or effect of NCAM was influenced by NCAM antibodies, NCAM fusion proteins and other NCAM ligands. Presumed NCAM  
30 ligands selected from a random peptide library were studied. The peptides were found to be able to bind Ig1. One specific peptide, which is not characterised further in the thesis, was shown to inhibit aggregation of neural cells and to stimulate neurite outgrowth. It is concluded  
35 that such ligands might be a valuable tool in the continued attempts to clarify the role of NCAM in the

developing nervous system as well as in synaptic plasticity. A possible medical use of the investigated peptides is neither an object of the thesis nor suggested therein. Furthermore, the thesis does not disclose the sequences of the investigated peptides.

US 5 625 040 relates to chondroitin sulphate proteoglycan (Phosphacan) and its use in enhancing regeneration of nerves by binding to NCAM. The Phosphacan sequence is 1616 amino acid residues long. Recombinant Phosphacan was obtained by cloning the encoding gene in a suitable vector. The gene was isolated using primers chosen in accordance with the identified amino acid sequences of some proteolytic fragments of Phosphacan. None of the fragments was suggested to possess a biological effect per se.

A stimulatory effect on the potential for neurite extension may be expected to have a beneficial effect in functions of the nervous system requiring plasticity of connections between nerve cells. Such functions include learning and memory and regeneration. It is therefore of considerable interest to identify substances with the capability to influence NCAM mediated signalling.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, novel compounds are provided, which promote extension of neurites in the central and peripheral nervous system.

More specifically, the invention concerns compounds which

(a) bind to the NCAM Ig1 domain and/or

(b) bind to the NCAM to the NCAM Ig2 domain

and are capable of stimulating neurite outgrowth from  
and/or proliferation of NCAM presenting cells. By the  
5 NCAM Ig1 domain and the NCAM Ig2 domain are understood  
the NCAM Ig1 polypeptide and the NCAM Ig2 polypeptide.  
These compounds include a) the group comprising the NCAM  
Ig2 polypeptide and fragments and mimics thereof and b)  
the group comprising the NCAM Ig1 polypeptide and  
10 fragments and mimics thereof.

Such compounds may be composed of natural occurring as  
well as synthetic amino acids, peptide nucleic acids  
(PNA) monomers and/or peptidomimetics.  
15

The present invention discloses a homophilic binding site  
in the NCAM molecule constituted by the combined  
(unified) Ig1 and Ig2 domain, which combination of  
domains hereinafter be notifiable as NCAM Ig1-Ig2 or as  
20 NCAM Ig1-Ig2 domains.

The invention includes thus compounds that bind to either  
the NCAM Ig1 domain (which corresponds to the above (a))  
or the NCAM Ig2 domain (which corresponds to the above  
25 (b)). These two domains form together the herein  
disclosed homophilic binding site.

According to the present invention said compounds within  
(a) and (b) may respectively belong to three below  
30 disclosed groups of compounds (the compound groups I, II  
and III) which are capable of activating neurite  
outgrowth.


As to the compound group I, the compound may in  
35 particular be a peptide which binds to the 1st domain of  
NCAM (NCAM Ig1) through a binding motif which comprises



at least 2 basic amino acid residues, preferably at least 2 basic amino acid residues within a sequence of 10 amino acid residues and more preferably at least 2 basic amino acid residues within a sequence of 3 amino acid residues.

5

Interesting peptides comprise the sequence:



10 wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^1$  is any amino acid residue,  
 $Xaa$  is any amino acid residue, and  
 $m, n, p, q$  and  $r$  independently are 0 or 1,

15 and wherein the basic amino acid residues preferably are lysine or arginine and  $r$  preferably is 1.

The nature of the amino acid residues  $Xaa$  and  $Xaa^1$  does not seem to be important. It appears that they may be any  
 20 amino acid residue. However,  $Xaa^1$  is preferably proline (P) or glutamic acid (E).

In even more preferred peptides  $r$  is 1 and at least one of  $m$  and  $n$  is 1.

25

Preferred peptides of the invention comprise the sequence  $(K/R)_{0-1} - K/R - X - K/R$ , wherein  $X$  has the same meaning as  $Xaa^1$ , suitably the sequence  $K/R - K/R - X - K/R$  or  $K/R - X - K/R$ , more suitably the sequence  $K/R - P - K/R$ ,  $K/R - K/R - P - K/R$ ,  
 30  $K/R - K/R - E - K/R$  or  $K/R - K/R - E - K/R$  most suitably the sequence  $K - P - K$ ,  $K - K - P - K$ ,  $K - K - E - K$  or  $K - K - E - R$ . Examples are the sequences A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), and A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

35

As to the compound group II, the compound may be a peptide that binds to that part of the homophilic binding site of NCAM Ig1-Ig2 which is constituted by the Ig1 domain.

5

The binding motif comprises at least 2 basic amino acid residues and at least 1 apolar amino acid, preferably at least 2 basic amino acid residues and 1 apolar amino acid residue within a sequence of 12 amino acid residues. More preferably, the binding motif comprises at least 2 basic amino acid residues and at least 1 apolar amino acid within a sequence of 8 amino acid residues. Most preferably, the binding motif comprises at least 2 basic amino acid residues separated by 3 amino acids in addition to 1 apolar amino acid with 1 adjacent acid amino acid separated by 1 of the basic amino acid residues by 1 amino acids. Such peptides comply with the general sequence.

20  $(Xaa^+) - (Xaa) - (Xaa) - (Xaa)_m - (Xaa^+) - (Xaa) - (Xaa^-)_n - (Xaa^h) - (Xaa)_o - (Xaa^h)_p,$

wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^-$  is a an acidic amino acid residue,  
 25  $Xaa^h$  is a apolar amino acid residue,  
 $Xaa$  is any amino acid residue, and  
 $m, n, o$  and  $p$  independently are 0 or 1,

and wherein the basic amino acid residues preferably are  
 30 lysine or arginine, the acidic amino acids preferably are glutamic acid or aspartic acid, the apolar amino acids are preferably leucine, isoleucine, valine or phenylalanine, and  $r$  preferably is 1.

35 Preferred peptides of the invention comprise the sequence  $(K/R) - X - X - X - (K/R) - X - (E/D) - (L/I/V/F) - X - (L/I/V/F),$  wherein

X is any amino acid residue, suitably the sequence (K/R)-X-(E/D)-(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(E/D), (K/R)-X-X-(K/R)-X-(E/D) or (K/R)-X-(L/I/V/F)-X-(L/I/V/F), more suitably the sequences (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F), (K/R)-X-X-(K/R)-X-(E/D)-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(L/I/V/F), even more suitably the sequences (K/R)-X-X-(K/R)-X-(E/D)-(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(L/I/V/F)-X-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F)-(L/I/V/F) and most suitably the sequence GRILARGEINFK (SEQ ID NO: 23).

As to the compound group III, the compound may be a peptide, that binds to that part of the homophilic binding site of NCAM Ig1-Ig2 which is constituted by the Ig2 domain.

The binding motif comprises at least 2 acidic amino acid residues and at least 1 apolar amino acid, preferably at least 2 acidic amino acid residues and 2 apolar amino acid residue within a sequence of 10 amino acid residues. More preferably, the binding motif comprises at least 2 acidic amino acid residues and at least 1 apolar amino acid within a sequence of 9 amino acid residues. Most preferably, the binding motif comprises at least 2 acidic amino acid residues separated by 4 amino acids, one of the acidic amino acids being separated by 1 amino acid from a basic amino acid and 2 adjacent apolar amino acids. Such peptides comply with the general sequence.

$(Xaa^-) - (Xaa) - (Xaa) - (Xaa)_m - (Xaa)_n - (Xaa^-) - (Xaa) - (Xaa^+) - (Xaa^h) - (Xaa^h)_p$ ,

wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^-$  is a an acidic amino acid residue,  
 $Xaa^h$  is an apolar amino acid residue,  
 $Xaa$  is any amino acid residue, and

m,n,o and p independently are 0 or 1,

and wherein the basic amino acid residues preferably are lysine or arginine, the acidic amino acids preferably are glutamic acid or aspartic acid, the apolar amino acids  
5 are preferably leucine, isoleucine, valine or phenylalanine, and r preferably is 1.

Preferred peptides of the invention comprise the sequence  
10 (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F), wherein X is any amino acid residue, suitably the sequence (E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F), (E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), (E/D)-X-X-X-X-(E/D)-X-(K/R)-(L/I/V/F), (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F) or (E/D)-X-X-(E/D)-X-(K/R)-  
15 (L/I/V/F), more suitably E/D)-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F) or (E/D)-X-X-(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), even more suitably the sequences (E/D)-X-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F) or (E/D)-X-X-X-  
20 (E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), and most suitably the sequence GEJSVGESKFFL (SEQ ID NO: 26).

The abbreviations of the amino acids follow the normal three and one letter codes: alanine (Ala,A), arginine  
25 (Arg,R), asparagine (Asn,N), aspartic acid (Asp,D), cysteine (Cys,C), glutamic acid (Glu,E), glutamine (Gln,Q), glycine (Gly,G), histidine (His,H), Isoleucine (Ile,I), leucine (Leu,L), lysine (Lys,K), methionine (Met,M), phenylalanine (Phe,F), proline (Pro,P), serine  
30 (Ser,S), threonine (Thr,T), tryptophan (Trp,W), tyrosine (Tyr,Y) and valine (Val,V).

In the present context, the term "amino acid" is intended to comprise naturally occurring amino acids as well as  
35 non-natural occurring amino acids. Non-natural occurring amino acids are i.a. modified naturally occurring amino

acids.

The peptides may be modified, for example by acetylation.

5 The invention also concerns compounds which are anti-NCAM  
Ig1 antibodies, which mimic the binding of the NCAM Ig2  
domain to the Ig1 domain. Such non-peptide molecules are  
e.g. PNAs or peptidomimetics. Examples of peptidomimetics  
are given in Marshall, G.R., Tetrahedron 49, 3547-3558  
10 (1993), and include oligo(N-substituted glycines),  
oligocarbamates, oligosulphones and oligosulfoxides.

The invention further concerns compounds which are non-  
peptide molecules, which mimic the binding of the NCAM  
15 Ig2 domain to the Ig1 domain.

The invention even further concerns the NCAM Ig2  
polypeptide, fragments or mimics thereof for use in the  
treatment of normal, degenerated or damaged NCAM  
20 presenting cells, said treatment consisting of  
stimulating neurite outgrowth from and/or proliferation  
of NCAM presenting cells.

The treatment may be a treatment of diseases and  
25 conditions of the central and peripheral nervous system,  
the muscles or various organs. The treatment may also be  
a stimulation of learning and memory.

In the present context, the term "conditions" is intended  
30 to cover any condition in need of treatment, whatever the  
need is in connection with a damage, disease or expected  
disease or in connection with a stimulation and/or  
improvement of normal conditions.

35 The invention also concerns the use of the NCAM Ig2  
polypeptide or fragments or mimics thereof in the

manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells.

5 The invention further concerns pharmaceutical compositions comprising one or more of the compounds according to the invention.

10 Further, the invention concerns a method of treating normal, degenerated or damaged NCAM presenting cells which method comprises administration of an effective amount of one or more of the compounds according to the invention.

15 The treatment may be a treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as  
20 multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-  
25 muscular connections, such as genetic or traumatic atrophic muscle disorders; of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis or of the heart,  
30 liver or bowel. The treatment may also be a stimulation of the ability to learn and/or of the memory.

The invention also concerns a prosthetic nerve guide, which guide comprises one or more of the compounds  
35 according to the invention.

## BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 shows the different forms of the neural cell adhesion molecule, NCAM. A) The main forms of NCAM all have similar extracellular parts consisting of five immunoglobulin-domains (Ig-domains) and two Fibronectin type III-domains (FnIII-domains). Three trans-membrane or membrane attached forms (NCAM-120, -140 and -180) are generated by alternative splicing. In addition, various soluble NCAM forms (NCAMs) exist. B) Individual NCAM-domains are numbered from the N-terminal (NH<sub>2</sub>), the most N-terminal domain being termed NCAM Ig1. An important alternatively spliced exon is the VASE exon that can be inserted in the region encoding the Ig4 domain of NCAM. The Ig5 domain can be glycosylated with polysialic acid (PSA).

Fig. 2 shows an identification of bead-coupled peptides binding NCAM domains. A) Libraries of bead-coupled decapeptides are incubated with the recombinant NCAM Ig1 domain. Beads that bind NCAM Ig1 are visualised by a staining reaction. Stained beads are isolated and microsequenced (Example 3 and 4). B) After evaluation of binding sequences, peptides corresponding to these sequences are synthesised as monomers, dendrimers (4-mers) or BSA-coupled 20-mers (Example 5). C) Structure of peptide dendrimers. Four peptide-monomers ("peptide") are coupled to a backbone consisting of three lysines.

Fig. 3 shows single hippocampal cells (Example 7 (2)) maintained in the absence (A) or presence (B) of C3d ( $5.4 \times 10^{-7}$  M).

Fig. 4 shows the peptide-sequences identified from combinatorial peptide libraries. A) 22 sequences identified from screening a combinatorial library with

NCAM Ig1. B) Peptides from A) comprising parts of the motif K/R-K/R-P-K/R-N/S emphasised in bold. The C3 peptide is underlined. C) Peptides comprising parts of the motif K/R-K/R-E-K/R-X-K/R-K/R emphasised in bold. The D3 peptide is underlined. D) Peptides containing the motif G-X-K/R-P-K/R emphasised in bold. The D4 peptide is underlined.

Fig. 5 shows the number of aggregates of primary hippocampal neurones formed after 24 h in culture in the presence of C3 dendrimer in concentrations of 1.07  $\mu$ M and 2.15  $\mu$ M (Example 7). The observed increase in the number of aggregates formed reflects an inhibition of the aggregation-process.

Fig. 6 shows the number of neuronal processes from primary hippocampal neurones formed after 24 h in culture in the presence of C3 dendrimer in concentrations of 1.07  $\mu$ M and 2.15  $\mu$ M (Example 7).

Fig. 7 gives a summary of the NCAM Ig1 binding peptides and their effect on neurite-outgrowth and aggregation in cell cultures of primary hippocampal neurones. Effect on neurite-outgrowth is measured in cultures of dissociated neurones as described in example 7 (2). For "neur", 0 indicates no effect, + indicates stimulatory effect, ++ indicates strong stimulatory effect on neurite outgrowth. For "agg", 0 indicates no effect, - indicates inhibitory effect, -- indicates strong inhibitory effect on aggregation, the inhibitory effect being reflected as an increased number of aggregates formed. The peptide names and/or numbers correspond to peptides of the sequences indicated in the figure. The peptides are all tested as dendrimers.

Fig. 8 shows the effect of C3 dendrimer on neurite



outgrowth in cocultures of neurones and fibroblasts (Example 7). Primary hippocampal neurones were grown on monolayers of fibroblasts with (LBN) or without (LVN) NCAM-140 expression. Neurite-outgrowth was increased on  
5 LBN fibroblast-monolayers compared to LVN fibroblast monolayers. This increase was inhibited by C3d in 0.54 or 5.4  $\mu\text{M}$ . On LVN monolayers, C3d stimulated neurite outgrowth.

10 Fig. 9 shows the effect of D3 and D4 dendrimers on neurite outgrowth from primary hippocampal neurones in the indicated doses in  $\mu\text{M}$ .

Fig. 10 shows the effect of C3 peptide dendrimer on  
15 neurite outgrowth from primary hippocampal neurones in the indicated doses in  $\mu\text{M}$ . Neurite outgrowth is measured as the mean length of the longest neurite ("axon length"). Primary hippocampal neurones from E18 rats were maintained for 21 h on fibronectin.

20 Fig. 11. shows neurite outgrowth measured from neurones maintained on plastic. Effect of C3d and control peptides (see Fig 7) on neurite outgrowth in a concentration of 0.54  $\mu\text{M}$ .

25 Fig. 12 shows the effect of various inhibitors of signal transduction on neurite outgrowth from primary hippocampal neurones maintained on fibronectin stimulated by C3d (0.54  $\mu\text{M}$ , see Example 7 2). Ver: verapamil (10  
30  $\mu\text{M}$ ), Cono: omega-conotoxin GVIA (0.27  $\mu\text{M}$ ), ploop1: NCAM Ig1 prepared in *Pichia pastoris* as described in example 1, 0.54  $\mu\text{M}$ .

Fig. 13 shows the effect of various inhibitors of signal  
35 transduction on neurite outgrowth from primary hippocampal neurones maintained on fibronectin stimulated

by C3d (0.54  $\mu$ M, see Example 7). Erb: erbstatin analogue (0.2  $\mu$ M), Pertus: Pertussis toxin (1  $\mu$ g/ml), CHD: peptide corresponding to CAM homology domain in FGF-R (175 or 350  $\mu$ M).

5

Fig. 14 shows the effect of NCAM Ig2, prepared in *Pichia pastoris* as described in example 2, on neurite outgrowth from primary hippocampal neurones maintained on fibronectin. NCAM Ig2 was added in the indicated concentrations in  $\mu$ g/ml (1  $\mu$ g/ml corresponds to 0.1  $\mu$ M). Neurite outgrowth is measured as the mean length of the longest neurite ("axon length").

10

Fig. 15 shows the effect of C3d and NCAM Ig2 added in combination on neurite outgrowth from primary hippocampal neurones maintained on fibronectin.

15

Fig. 16 shows the effect of C3d in the indicated concentrations in  $\mu$ M on proliferation of primary hippocampal neurones measured as incorporation of BrdU as described in example 8.

20

Fig. 17 shows the predicted amino acid sequence of human NCAM, 140 KD isoform precursor (SWISS-PROT: locus NCA1-HUMAN, accession no. P13591).

25

Fig. 18. The dimer of the first two domains of NCAM, (Ig1-Ig2). A) Ribbon presentation of the dimer. light grey marks the binding site residues in Ig1 and Ig2. B) Space filling model of the two first domains of NCAM the dimer of the first two domains of NCAM, (Ig1-Ig2). The residues of the binding sites in the two domains are light grey. Key residues in the binding between Ig1 and Ig2 are marked with numbers corresponding to their position in the NCAM sequence. C) Ribbon presentation of the dimer showing the key electrostatic and hydrophobic

30

35

interactions used in the modeling of the dimer structure.

Fig. 19. Effect of Ig domain 2, the monomeric Ig2-peptide and its derivatives on aggregations in primary cultures of dissociated hippocampal cells of rat embryos (E18). Cultures were grown for 24 h. The number of aggregates in cultures treated with compounds is expressed as a percentage of the number of aggregates in control cultures ( $100 \pm 10$ ). Four individual experiments were performed. Results are given as mean  $\pm$  SEM. (a). Comparison of the effects of Ig domain 2 (Ig2) and Ig2-peptide (Ig2-p), a dose-response study. (b). Comparison of the effects of Ig2-peptide (Ig2-p) and Ig2 peptides in which either Arg-2, Arg-6 and Ile-9 (P2-3S) or Arg-2, Arg-6, Glu-8 and Ile-9 (P2-4S) were substituted with Ser. The peptides were used at a concentration  $180 \mu\text{M}$ .

Fig. 20. Effect of Ig domain 2 (Ig2) and Ig2-peptide (Ig2-p) on neurite outgrowth from hippocampal neurons grown for 24 h. The length of neurites in treated cultures is expressed as a percentage of the length of neurites in control cultures. Four individual experiments were performed. Results are given as mean  $\pm$  SEM.

Fig. 21. Effect of Ig2-peptide (Ig2-p) and its derivatives (P2-3S and P2-4S) on neurite outgrowth from hippocampal neurons grown for 24 h. The length of neurites in treated cultures is expressed as a percentage of the length of neurites in control cultures. Four individual experiments were performed. Results are given as mean  $\pm$  SEM.

Fig. 22. Phase contrast micrographs of a 24 h low-density culture of dissociated cells from hippocampus grown in the absence (a) or presence (b) of  $3.6 \mu\text{M}$  Ig2-peptide (dendrimer) encompassing residues 191-202 of the Ig

domain 2.

Fig. 23. Effect of Ig domain 1 of NCAM (Ig1, 25  $\mu$ M), FGFR antibodies ( $\alpha$ -FGFR, diluted 1:2000), CAM homology domain peptide (CHD, 200  $\mu$ M) and U-73122, an inhibitor of phospholipaseC $\gamma$  (5 $\mu$ M), on neurite outgrowth from hippocampal neurons. Cultures were grown in the absence or in the presence of 3.6  $\mu$ M Ig2-peptide (dendrimer, Igpd). The length of neurites in treated cultures is expressed as a percentage of the length of neurites in control cultures. Four individual experiments were performed. Results are given as mean  $\pm$  SEM.

Fig. 24. Effect of Ig1-peptide (Ig1-p) on aggregation (left, 250  $\mu$ g/ml) and neurite outgrowth (right, 5  $\mu$ g/ml) from hippocampal neurons grown for 24 h. The number of aggregates and the length of neurites is expressed normalised relative to control cultures. Three individual experiments were performed. Results are given as mean  $\pm$  SEM.

Fig. 25. Effect of mutations in a double Ig domain (Ig1-2) of NCAM on neurite outgrowth from hippocampal neurons. The following mutations were made in NCAM (20-208): R192A, R196A, and E198A. The length of neurites in treated cultures is expressed as a percentage of the length of neurites in control cultures. Five individual experiments were performed. Results are given as mean  $\pm$  SEM.

30

#### DETAILED DESCRIPTION OF THE INVENTION

In the nervous system, the ability to remodel connections between nerve cells is of major importance in the regeneration and well as in learning. Therefore, it is of considerable interest to identify substances that promote

35

such processes. Much effort has been concentrated on identifying substances that stimulate neuronal survival and neuritic outgrowth *in vitro* as such substances will be expected to possess a potential to stimulate regeneration and learning. The neural cell adhesion molecule (NCAM) is believed to be important for the development and remodelling of neuronal connections and it is therefore of interest to identify ligands capable of stimulating NCAM-functions. It has previously been shown that antibodies against the Ig3 domain of NCAM can stimulate neurite outgrowth.

The present invention is based on the surprising finding that the NCAM Ig2 domain strongly stimulates the outgrowth of neurites from NCAM presenting cells. Thus, it has been found that NCAM Ig2 is a ligand of the NCAM Ig1 domain. It has further been found that the NCAM Ig2 domain stimulates neurite outgrowth by activation of specific signal transduction pathways.

Likewise, the present invention discloses the NCAM Ig1 domain as a ligand of the NCAM Ig2 domain and being capable of strong stimulation of the outgrowth of neurites from NCAM presenting cells by activation of specific signal transduction pathways.

The inventors have also, by means of combinatorial chemistry, identified small peptides which stimulate neurite outgrowth. Active peptides selected from a peptide library have been identified, and a putative motif comprising two or more basic amino acid residues has been identified. The peptides have been shown to stimulate the same specific signal transduction pathways as the NCAM Ig2 domain.

35

The results show that ligands of NCAM Ig1, either the NCAM Ig2 domain or small functional mimics hereof, which are capable of activating specific signalling pathways, can promote neurite outgrowth and thereby be of benefit in regeneration and learning. Other functional mimics of the NCAM Ig2 domain, such as antibodies and non-peptide molecules may be beneficial in the same way. Therefore, the present invention provides compounds and compositions which are or comprise small peptides, polypeptides, antibodies and non-peptide molecules recognising the NCAM Ig1 domain. When applied to tissue containing NCAM-expressing cells these compounds and compositions will promote NCAM function. The compounds and the compositions can be applied to promote functions of the nervous system, the muscles and any other NCAM-expressing tissues, including various organs.

In its broadest aspect, the present invention relates to compounds which bind to the NCAM Ig1 domain and/or the NCAM Ig2 domain and which are capable of stimulating neurite outgrowth from and/or proliferation of NCAM presenting cells. Such compounds may be a peptide or PNA sequence constituting the NCAM Ig2 domain, a fragment thereof or a mimic thereof.

Also, such compounds may be a peptide or PNA sequence constituting the NCAM Ig1 domain, a fragment thereof or a mimic thereof.

In the present context, a mimic of the Ig2 domain and the NCAM Ig1 domain should be understood to be any compound which binds to the NCAM Ig1 domain or the Ig2 domain, and through said binding stimulates neurite outgrowth from and/or proliferation of NCAM presenting cells. Mimics may be peptides, peptide derivatives, antibodies and non-peptide compounds such as small organic compounds, sugars

and fats, as well as peptidomimetics.

In accordance with the present invention, novel compounds are provided, which promote extension of neurites in the central and peripheral nervous system. Surprisingly, it has been found that the compounds of the invention are able to promote formation and plasticity of neural connections.

It appears from the above, that the compounds of the present invention belong to three disclosed groups of compound (the compound groups I, II and III) which are capable of binding to the NCAM Ig1-Ig2 domains and thereby activate neurite outgrowth.

Further to compound group II, 22 peptides which were able to bind to recombinant, labelled neural cell adhesion compound Ig1 (NCAM Ig1) in vitro have been identified from a peptide library.


The 22 sequences are ASKKPKRNIKA (SEQ ID NO:1), AKKERQRKDTQ (SEQ ID NO:2), ARALNWGAKPK (SEQ ID NO:3), AGSAVKLKKKA (SEQ ID NO:4), AKYVLIPIRIS (SEQ ID NO:5), ASTKRSMQGI (SEQ ID NO:6), ARRAILM(Q/T/N)-AL (SEQ ID NO:7), AYYLIVRVNRI (SEQ ID NO:8), ATNKKTGRRPR (SEQ ID NO:9), AKRNGPLINRI (SEQ ID NO:10), AKRSVQKLDGQ (SEQ ID NO:11), ARQKTMKPRRS (SEQ ID NO:12), AGDYNPDLDLDR (SEQ ID NO:13), ARKTRERKSKD (SEQ ID NO:14), ASQAKRRKGPR (SEQ ID NO:15), APKLDRMLTKK (SEQ ID NO:16), AKKEKPNKPND (SEQ ID NO:17), AQMGRQSIDRN (SEQ ID NO:18), AEGGKKKKMRA (SEQ ID NO:19), AKKKEQKQRNA (SEQ ID NO:20), AKSRKGNSSLM (SEQ ID NO:21), ARKSRDMTAAIK (SEQ ID NO:22).

Three peptides, C3 (SEQ ID NO:1), D3 (SEQ ID NO:2) and D4 (SEQ ID NO:3) (Fig. 4) were further investigated for their ability to bind the NCAM Ig1 domain using plasmon

surface resonance analysis and selected according to their ability to inhibit aggregation of neurones and stimulate neurite outgrowth. By sequence analysis of these peptides and scrambled peptides, a motif for binding to NCAM Ig1 could surprisingly be identified. The motif includes positively charged amino acids in a relatively loose sequence-order, K/R (aa)<sub>0-8</sub> K/R, preferably K/R (aa)<sub>0-1</sub> K/R, wherein K and R designate lysine and arginine respectively and the positively charged amino acids are separated by up to 8 amino acid (aa) residues. Preferably, however, the positively charged amino acids are adjacent or separated by only one amino acid residue.

Analysis of the active peptides isolated from the peptide library suggests that the motif may comprise more than two positively charged amino acids, for example three or four basic amino acids.

Preferred peptides comprise the sequence:



wherein  $Xaa^+$  is a basic amino acid residue,

$Xaa^1$  is any amino acid residue,

$Xaa$  is any amino acid residue, and

$m, n, p, q$  and  $r$  independently are 0 or 1.

and wherein the basic amino acid residues preferably are lysine or arginine and  $r$  preferably is 1.

The nature of the amino acid residues  $Xaa$  and  $Xaa^1$  does not seem to be important. It appears that they may be any amino acid residue. However,  $Xaa^1$  is preferably proline (P) or glutamic acid (E).



In even more preferred peptides  $r$  is 1 and at least one of  $m$  and  $n$  is 1.

Preferred peptides of the invention comprise the sequence  
5 (K/R)<sub>0-1</sub>-K/R-X-K/R), wherein X has the meaning of Xaa<sup>1</sup>,  
suitably the sequence K/R-K/R-X-K/R or K/R-X-K/R, more  
suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-  
E-K/R or K/R-K/R-E-K/R and most suitably K-P-K, K-K-P-K,  
K-K-E-K or K-K-E-R. Examples are the sequences A-S-K-K-P-  
10 K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID  
NO:2), and A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

According to the invention, peptides comprising the above  
sequence may be a part (hereinafter called a fragment) of  
15 the NCAM Ig2 domain or a mimic of the NCAM Ig2 domain.  
Furthermore, the peptides may bind to the Ig2 binding  
site of the Ig1 domain or to a different binding site on  
the Ig1 domain. If the binding site is not the "normal"  
Ig2 binding site, the binding will mimic the normal  
20 binding and result in neurite outgrowth and/or  
proliferation of NCAM presenting cells in the same way.

It is clear that the peptides of the invention are not  
limited to the decapeptides identified and selected from  
25 the synthetic peptide library. These peptides only served  
as tools for identifying a motif in peptide ligands  
expected to bind to the NCAM Ig1 domain.

The inventors have further disclosed a small synthetic  
30 peptide, called IG2-P and it is surprisingly shown, that  
this strongly stimulates neurite outgrowth (see figures  
20-21). By means of nuclear magnetic resonance (NMR) (see  
figure 18), the NCAM Ig2 domain was shown to belong to  
the I-set of Ig-domains (ref) as does the NCAM Ig1 domain  
35 that may be capable of binding to the NCAM Ig2 domain. By  
analysing the chemical shifts of the individual amino

acid residues a distinct interaction site between the Ig1 and the Ig2 domain was surprisnly found. It was strikingly found that the total interaction site consisted of residues from both the Ig1 and the Ig2 domain of NCAM. Thus, parts of these two domains together formed one distinct interaction site. In the Ig2 domain, the amino acids Arg-192, Arg-196, Glu-198, Ile-199 and Phe-201 were particularly important for the binding according to the chemical shift studies and the indicated model. Similarly, in the Ig1 domain, the amino acids Glu-30, Glu-35 and Lys-37, Phe-38 and Phe-39 appeared to be particularly important for the binding (see figure 18).

Further investigations with mutations of the amino acids Arg-192, Arg-196, Glu-198, Glu-30, Glu-35 and Lys-37 showed that these mutations inhibited the binding function of the NCAM Ig2 domain. From investigation of the Ig2 and the Ig1 structure solved by NMR two peptides were then constructed by the inventors and two particular regions in the three dimensional structure of the entire domain were revealed as being of particular and surprising importance.

Thereafter, a presumingly corresponding sequence of 12 amino acids from the two-dimensional amino acid sequence of the entire Ig2 domain of NCAM (residues 191-202) (see figure 17) and a sequence of 12 amino acids from the Ig1 domain (residues 29-40) were identified. Two peptides corresponding to these short sequences were then synthesised and shown to promote neurite outgrowth from neurons in cell cultures and thereby to posses a potential to promote regeneration and other forms of structural plasticity of cells and tissues expressing NCAM.

The identified Ig2-peptide, called IG2-P, was

demonstrated to have the sequence GRILARGEINFK (SEQ ID NO:23) and thus shares no similarity to other neuritogenic peptides, either derived from the entire NCAM-sequence or found to bind the NCAM-molecule. In addition, for control purposes, the invention provides 2 peptides sequences (SEQ ID NO:24 and SEQ ID NO:25), derived from the Ig2-p sequence, which peptides do not promote neurite outgrowth. The use of these polypeptides for control purposes are explained in more detail in example 5. The Ig1-peptide, called IG1-P, appeared to have the sequence GEISVGESKFFL (SEQ ID NO:26) sharing no homology to known neuritogenic factors. The four sequences found were

GRILARGEINFK (SEQ ID NO:23)  
GSILASGESNFK (SEQ ID NO:24)  
GRILARGSSNFK (SEQ ID NO:25)  
GEISVGESKFFL (SEQ ID NO:26)

The present invention provides thus compounds or compositions comprising the IG1-P-peptide and/or the IG2-P-peptide or derivatives hereof, such as peptide-analogues, peptide-fragments, polypeptides comprising the IG1-P-sequence or the IG2-P-sequence or analogues hereof and non-peptide molecules derived from the herein presented IG1-P-peptide and IG2-P-peptide, which are capable of stimulating neurite outgrowth from neurons, neuronal cell lines or tissues.

These mentioned compounds and compositions can be used to treat degenerative conditions affecting the peripheral or central nervous system, muscle and other tissues expressing NCAM as well as other conditions in which a stimulation of NCAM function is beneficial.

The present invention also includes an additional and


surprising finding to the above disclosure, that the specific signal transduction pathways of neurite outgrowth appears to be stimulated by the NCAM Ig2 domain and fragments and mimics thereof furthermore the NCAM Ig1 domain and fragments and mimics thereof. and the small peptides comprising two or more basic amino acid residues. It was thus found that the specific signal transduction pathways were also stimulated by the Ig2-peptide, Ig2-p described above. Thus, the inventors have identified a homophilic binding site in NCAM to which the NCAM domains Ig1 and Ig2 contribute. Further it is demonstrated that four ligands binding to the binding site constituted by the NCAM Ig1-Ig2 domains, namely the NCAM Ig2 domain, the Ig2-p peptide derived from the NCAM Ig2 sequence, the Ig-1-p peptide derived from the NCAM Ig1 sequence and the C3 peptide and related peptides identified from a combinatorial peptide library, all promote neurite outgrowth. All four NCAM Ig1-Ig2 ligands belong to the same new class of compounds capable of binding the NCAM Ig1-Ig2 domains thereby activating signal transduction leading to neurite outgrowth.

In general, the present invention discloses novel compounds which are able to stimulate and promote the outgrowth of neurites from and/or NCAM presenting cells within the central and peripheral nervous system. Furthermore, the novel compounds according to the invention appear to promote formation and plasticity of neural connections. As it appears from the above, it was revealed by the inventors, that the compounds of the invention belong to three disclosed groups of compounds (the compound groups I, II and III) and after the compound group I has been detailed the compound group II will be described in the following.

35

The compound group II contains compounds, which may be

peptides which bind to that part of the homophilic binding site of NCAM Ig1-Ig2 which is constituted by the Ig1 domain. Such peptides appear to have the general sequence, including any functional derivative thereof, as follows



wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^-$  is a an acidic amino acid residue,  
 $Xaa^h$  is a apolar amino acid residue,  
 $Xaa$  is any amino acid residue, and  
 $m, n, o$  and  $p$  independently are 0 or 1,


and wherein the basic amino acid residues preferably are lysine or arginine, the acidic amino acids preferably are glutamic acid or aspartic acid, the apolar amino acids are preferably leucine, isoleucine, valine or phenylalanine, and  $r$  preferably is 1.

A peptide according to group II comprises the sequence  $(K/R) - X - X - X - (K/R) - X - (E/D) - (L/I/V/F) - X - (L/I/V/F)$ , wherein  $X$  is any amino acid residue, suitably the sequence  $(K/R) - X - (E/D) - (L/I/V/F) - X - (L/I/V/F)$ ,  $(K/R) - X - X - X - (K/R) - X - (E/D)$ ,  $(K/R) - X - X - (K/R) - X - (E/D)$  or  $(K/R) - X - (L/I/V/F) - X - (L/I/V/F)$ , more suitably the sequences  $(K/R) - X - X - X - (K/R) - X - (E/D) - (L/I/V/F)$ ,  $(K/R) - X - X - (K/R) - X - (E/D) - (L/I/V/F)$  or  $(K/R) - X - X - X - (K/R) - X - (L/I/V/F)$ , even more suitably the sequences  $(K/R) - X - X - (K/R) - X - (E/D) - (L/I/V/F) - X - (L/I/V/F)$ ,  $(K/R) - X - X - X - (K/R) - X - (L/I/V/F) - X - (L/I/V/F)$  or  $(K/R) - X - X - X - (K/R) - X - (E/D) - (L/I/V/F) - (L/I/V/F)$  and most suitably the sequence GRILARGEINFK (SEQ ID NO: 23).

Regarding the compound group III, the compounds of this group may likewise be a peptide that binds to the part of

the homophilic bindingsite of NCAM Ig1-Ig2 that is constituted by the Ig2 domain. Such peptides appear to have the general sequence, including any functional derivative thereof, as follows

5



10

wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^-$  is a an acidic amino acid residue,  
 $Xaa^h$  is an apolar amino acid residue,  
 $Xaa$  is any amino acid residue, and  
 $m, n, o$  and  $p$  independently are 0 or 1,

15

and wherein the basic amino acid residues preferably are lysine or arginine, the acidic amino acids preferably are glutamic acid or aspartic acid, the apolar amino acids are preferably leucine, isoleucine, valine or phenylalanine, and  $r$  preferably is 1.

20

A peptide within group III comprises the sequence  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$ , wherein  $X$  is any amino acid residue, suitably the sequence  $(E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$ ,  $(E/D) - X - (K/R) - (L/I/V/F) - (L/I/V/F)$ ,  $(E/D) - X - X - X - X - (E/D) - X - (K/R) - (L/I/V/F)$ ,  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F)$  or  $(E/D) - X - X - (E/D) - X - (K/R) - (L/I/V/F)$ , more suitably  $E/D) - X - X - (E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$  or  $(E/D) - X - X - (E/D) - X - (K/R) - (L/I/V/F) - (L/I/V/F)$ , even more suitably the sequences  $(E/D) - X - X - X - X - (E/D) - X - (K/R) - (L/I/V/F) - (L/I/V/F)$ ,  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$  or  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F) - (L/I/V/F)$ , and most suitably the sequence GEJSVGESKFFL (SEQ ID NO: 26).

35

Compounds provided in the present invention also comprise peptides that bind to the NCAM Ig1domain and stimulates

neurite outgrowth.

The peptides may be modified, for example by substitution of one or more of the amino acid residues. Both L-amino acids and D-amino acids may be used. Other modification may comprise derivatives such as esters, sugars, etc. Examples are methyl and acetyl esters. Polymerisation such as repetitive sequences or attachment to various carriers well-known in the art, e.g. lysine backbones or protein moieties such as bovine serum albumin (BSA) is also an aspect of the invention.

The invention also concerns non-peptide mimics of the NCAM Ig2 domain or the peptides defined above. In the present context, such mimics should be understood to be compounds which bind to or in other ways interact with the NCAM Ig1 domain and/or the NCAM Ig2 domain and thereby stimulate neurite outgrowth from and/or proliferation of NCAM presenting cells.

In a further aspect, the present invention relates to compounds which are anti-NCAM Ig1 antibodies, or antibodies recognising the part of Ig2 contributing to the NCAM Ig1-Ig2 binding site disclosed herein.

The antibodies may be monoclonal or polyclonal. Recombinant antibodies such as chimeric and/or humanised antibodies are also a part of the invention.

In a further aspect, the present invention relates to the NCAM Ig2 polypeptide, a fragment or a mimic thereof for use in the treatment of a normal, degenerated or damaged NCAM presenting cells. The treatment is a treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs. Only NCAM presenting cells may respond to such a treatment.

The invention also relates to a pharmaceutical composition and a medicament comprising one or more of the compounds defined above.

5

In yet a further aspect, the present invention relates to methods of treating normal, degenerated or damaged NCAM presenting cells in vitro or in vivo, the method involving administering an effective amount of one or  
10 more compounds as defined above.

The treatment comprises treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve  
15 damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting  
20 the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases and conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; and treatment of diseases and  
25 conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidneys such as nephrosis and of the heart, liver and bowel.

30 Another aspect of the invention is the use of the compounds according to the invention in combination with a prosthetic nerve guide.

Yet another aspect of the invention is the use of the  
35 compounds according to the invention in the stimulation of the ability to learn and/or of the memory.



To be able to identify candidate ligands capable of stimulating NCAM function, the inventors have established a simple culture system (aggregate cultures) that permits a quantitative evaluation of the effect of various ligands. Hippocampal cells are provided from rat embryos. The cells are grown in a defined medium and dissociated cells are seeded in microtiter plates. After 24 h, the amount of aggregates are counted. Compounds to be tested are added to the cell suspension immediately before seeding of cells in the microwells. When NCAM Ig1 binding ligands are present during the aggregation of cells, smaller, but more numerous cell aggregates are seen when quantified 24 h after seeding of cells. The inhibiting effect of the ligands results in a blockage of the formation of large aggregates from many small aggregates as the adhesion properties of NCAM are blocked. Thus small, but more numerous cell aggregates are seen in the presence of active ligands.

Such an effect was observed when different ligands of the NCAM Ig1-Ig2 domain were present during the aggregation of cells. Thus, the entire recombinant Ig2 and a synthetic peptide derived from either the Ig2 sequence (Ig2-p) (SEQ ID NO:23) or the Ig1 sequence (Ig1-p) (SEQ ID NO:26) and peptide ligands of NCAM-Ig1 identified from libraries of synthetic peptides (SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3) inhibited aggregation in the described cell culture system.

The system allows the examination of cell adhesion, cell migration and formation of processes in the treated cells leading to possibly neurite outgrowth. To investigate the latter further, neurite extension from single neurones may be studied. Cells are prepared as in the aggregation study and seeded on a substrate of plastic or

fibronectin. The cells are then maintained for a suitable time, whereafter the neurite outgrowth is analysed by a measurement of the neurite extension, for example by a computer-assisted image analysis program. The mean length  
5 of the longest neurite of each cell was measured for neurites longer than 10  $\mu$ M (see Figure 2). In addition, the mean number of branchpoints per neurite and the mean number of neurites per cell were determined. NCAM Ig1-Ig2 ligands to be tested are added immediately before seeding  
10 the cells. (SEQ ID NO: 1,2,3,23,26).

Similarly, peptides derived from the binding site in NCAM Ig1-Ig2 were added immediately before seeding the cells.

15 To investigate the mechanisms of the neuritogene effect, one of the ligands, C3 (SEQ ID NO:1) was added in combination with various compounds known to inhibit NCAM dependent signalling. The following compounds were found to inhibit the stimulatory effect of C3 on neurite  
20 extension: verapamil ("ve" inhibitor of L-type voltage dependent calcium channels), omega-conotoxin GVIA ("co" inhibitor of N-type voltage dependent calcium channels), pertussis toxin ("pertus" inhibitor of certain G-proteins), an erbstatin analogue ("erb"; inhibitor of  
25 certain tyrosine kinases), antibody to an acidbox epitope in fibroblast growth factor receptors (FGF-Rs) (inhibitor of NCAM-FGF-R binding and signalling), a peptide corresponding to the so-called CAM homology domain (CHD) (inhibitor of NCAM-FGF-R binding and signalling).

30 In addition, the neuritogenic effect of C3 was completely abrogated by the NCAM Ig1 domain in solution. These results show that the ligands such as C3 stimulate neurite outgrowth by binding to the NCAM Ig1 domain and  
35 thereby activating signalling pathways in the neurone

that are sensitive to the above mentioned inhibitor-compounds.

5 The endogenous ligand of NCAM Ig1, NCAM Ig2 was tested for its effect on neurite outgrowth from primary hippocampal neurones maintained on a substrate of fibronectin. NCAM Ig2 was added to the culture-wells immediately before seeding of cells. It is found that NCAM Ig2 stimulates neurite outgrowth similar to the C3 peptide. The maximal neuritogenic effect of NCAM Ig2 was found at the same concentration at which the C3 peptide had its maximal neuritogenic effect.

15 When the NCAM Ig2 domain was tested in combination with compounds known to inhibit NCAM dependent signalling as described for C3 above, the neuritogenic effect was inhibited in the same way. It thus appears that the endogenous ligand NCAM Ig2 and the artificial ligand C3 both bind to NCAM Ig1 and that both NCAM Ig2 and C3 stimulate neurite extension, which is believed to be due to activation of identical signal transduction pathways.

When synthetic peptides derived from the binding site of NCAM Ig1 or NCAM Ig2 were added to the cell cultures, neurite outgrowth was stimulated. Thus, the effect of Ig2 can be mimicked by small synthetic peptides constituting fragments of the NCAM Ig1-Ig2 sequence. Hence, neurite outgrowth appeared to be promoted firstly by the intact Ig2 domain in its form of a recombinant polypeptide, secondly by fragments of the NCAM-Ig1 and NCAM-Ig2 domain and thirdly by NCAM-Ig1 binding peptides that were unrelated to the peptides derivable from the sequence. Therefore the inventors have demonstrated the novel and surprising principle that neurite outgrowth is promotable by compounds that bind to the NCAM Ig1 domain and/or to parts of the NCAM Ig1-Ig2, which are being involved in

homophilic NCAM binding.

In order to control the specificity of the Ig2-peptide (Ig2-p), two control peptides, P2-3S and P2-4S, were synthesised and found to have no neuritogenic effect. Reference is made to example 5). The sequence of the P2-3S peptide, GSILASGESNFK (SEQ ID: 24) corresponds to the sequence of Ig2-p, in which Arg-2, Arg-6 and Ile-9 are substituted with serines. The sequence of P2-4S peptide, GSILASGSSNFK (SEQ ID NO: 25) corresponds to the sequence of Ig2-p, in which Arg-2, Arg-6, Glu-8 and Ile-9 are substituted with serines showing that the mutated amino acid residues are important for the neuritogenic effect of the Ig2-p peptide.

NCAM Ig2 and C3 were also tested for their effect on neurite outgrowth when added in combination. The effects were found to be non-additive. The results further indicate that NCAM Ig2 and C3 stimulate neurite extension by identical mechanisms. They both bind to the NCAM Ig1 domain and thereby activate identical signalling pathways leading to neurite outgrowth.

Putative artificial ligands may be selected and identified from peptide or non-peptide libraries. Any peptide library may be used. Synthetic peptide libraries as well as libraries containing fragmented natural occurring proteins, may be used in the search for useful peptides. Any kind of libraries comprising non-peptide compounds may similarly be used.

Peptides are short molecules consisting of amino acids in a linear sequence. Amino acids are the building blocks of naturally occurring proteins which consist of long folded chains of amino acids. Thus, peptides characterised by a certain sequence of amino acids may mimic a certain area

of a protein. Naturally occurring proteins consist of L-amino acid residues. However, artificial peptides may also consist of or comprise D-amino acid residues. By combinatorial chemistry, mixtures of beads carrying peptides of equal length can be constructed, in which each bead carries peptides of a unique sequence (Lam et al., 1991). Such a mixture of peptides on beads is called a peptide library.

10 In the present invention, peptides were identified by screening synthetic random peptide libraries comprising resin-bound decapeptides with purified recombinant NCAM Ig1. The synthesis of the resin-bound one-bead one-peptide library was performed using the portioning, mix  
15 procedure (Furka, Å., Sebestyén, F., Asgedom, M. And Dibó, G. (1991) Int. J. Pep. Prot. Res. 37, 487-493). Polyethylene syringes served as reaction vessels throughout the synthesis. Screenings were done by incubating the resin with biotinylated NCAM Ig1.  
20 Subsequently the resin was incubated with avidin-alkaline phosphatase. The substrates BCIP/NBT (Sigma) were added as described by the procedure by Lam et al. (1992) and stained beads removed for micro sequencing.

25 The most intensely stained beads were selected under stereo microscope and sequenced on an ABI 470A equipped with an ABI 120A HPLC. 22 NCAM Ig1 binding peptide sequences were identified (FIG. 4(A); SEQ ID NO:1 to SEQ ID NO:22).

30

It is to be understood that the method chosen for identification and selection of interesting peptides is not critical for the identification of a putative motif.

35 Peptide sequences to be synthesised were chosen by aligning the obtained sequences and examining these for

repeated patterns revealing putative motifs (FIG 4(B)-(D)).

5 The three peptides called C3, D3 and D4 (FIG 4(B)-(D)) were synthesised and their binding to the NCAM Ig1 domain evaluated by plasmon surface resonance analysis. When immobilised on a sensor chip, peptide dendrimers (4 peptides linked to a lysine backbone (Fig. 2(C)) were used in order to secure an exposure of at least one peptide for  
10 binding to NCAM Ig 1 in solution. All three peptides bound the NCAM-Ig1 in solution. The three peptides were further tested for their effect on neurite outgrowth. All three peptides strongly stimulated neurite outgrowth. Moreover, the peptides inhibited aggregation of cells.

15

To investigate which properties of the peptides are important for the effect, various control-peptides of the C3-sequence were constructed and tested.

20 To investigate the role of the individual residues in the C3-sequence, so-called scrambled peptides, comprising the same residues as C3 but in a different sequence, were constructed (121, 114 and C3scr in Fig. 7). Similarly, scrambled peptides corresponding to the residues in the  
25 D3 and D4 sequences were constructed (scrambled D3 and scrambled D4 in Fig. 7). Furthermore, peptides containing the C3-sequence in which basic amino acids (Ks and Rs) were substituted with alanines were constructed (116 - 119 in Fig. 7) to explore the role of these particular  
30 amino acids. Likewise, a peptide corresponding to the C3-sequence in which the proline-residue (Xaa<sup>1</sup>) was substituted with an alanine was constructed, as prolines are generally considered important for the structure of peptides. Substituting the proline with an alanine does  
35 not change the effect. Likewise, one basic amino acid could be alanine substituted without a change in effect.

In contrast, peptides with two to four alanine substitutions of the basic residues had no effect on aggregation indicating that these residues are important for the effect of C3. To further investigate the role of the basic amino acid residues in C3, a peptide containing the C3-sequence in which the basic amino acids were modified by acetylation was constructed. The acetylation removes the charges from these residues while preserving the ability to form hydrogen bonds. A peptide in which four basic amino acids were modified by acetylation (C3dacetyl. K(120) in Fig. 7) inhibited aggregation as C3 indicating that not only the charges but also other properties of the basic amino acids such as the ability to form hydrogen bonds must be important for the effect of C3. Similar aggregate cultures were prepared in the presence of C3 as monomer, dendrimer (C3d) or as BSA-coupled 20-mer. Different forms of the C3 peptide were tested. It was found that monomeric, dendrimeric and BSA-coupled forms of C3 have similar effects on aggregation. The dendrimer of the C3 sequence is the most potent form, presumably due to the ability to link several of the receptor domains. To verify that the receptor is in fact the NCAM Ig1 domain, the cells were incubated with this domain prepared in *Pichia pastoris* in solution as described in Example 1. The presence of the NCAM Ig1 domain abrogated the effect of C3 demonstrating an interference with NCAM-mediated cell adhesion of C3. These experiments show that the here identified NCAM Ig1 binding peptides influence NCAM mediated cell adhesion and thereby increase the number of cell aggregates and neuronal processes formed in cultures of primary neurones grown at high densities.

The substitution of only two basic amino acids in the sequence of the C3 peptide completely abolished the neuritogenic effect. Thus, when two to four lysines and

arginines in the sequence were substituted by alanines, the neurite stimulatory effect was completely abrogated. This shows that the basic amino acids in the C3 sequence are crucial for its effect. Surprisingly, peptides in which the same amino acids were modified by acetylation have some effect on cell adhesion and neurite outgrowth, although not to the same extent as the intact C3 peptide, showing that not only the charges but also other properties of the basic amino acids, such as the ability to form hydrogen bonds, are of importance. In addition, the effect of the intact peptide can be blocked by equimolar concentrations of the NCAM Ig1 domain in solution. This shows that the peptide works by binding to the NCAM Ig1 domain expressed by neurones.

The effect of the ligands on proliferation and cell growth was also tested. The C3 peptide was found to initially stimulate proliferation and cell growth. After this initial promotion of proliferation, the peptides stimulate differentiation by increasing neurite outgrowth and at the same time suppressing proliferation. Thus the net effect on proliferation depends on the growth status of the cells. An effect on proliferation has been shown for primary cell cultures from the hippocampus cells and cultures of rat pheochromocytoma cell line PC12 cells. Accordingly, the ligands stimulate neurite outgrowth from and/or proliferation of NCAM presenting cells.

As it clearly has been described discloses this invention three groups, group I, II and III, of compounds, and a compound of the group I of the invention may be a peptide which binds to the NCAM Ig1 domain through a binding motif which comprises at least 2 basic amino acid residues. Peptides comprising at least 2 basic amino acid residues within a sequence of 10 amino acid residues, suitably within a sequence of 3 amino acid residues, are




believed to be very interesting compounds for the purpose of the present invention.

5 The analysis of the isolated peptide ligands revealed that the ligands may advantageously comprise more than two basic amino acids.

In accordance herewith, interesting peptides within group I comprise the sequence

10



wherein

$Xaa^+$  is a basic amino acid residue,

15  $Xaa^1$  is any amino acid residue,

$Xaa$  is any amino acid residue, and

$m, n, p, q$  and  $r$  independently are 0 or 1.

20 The basic amino acid residues are preferably selected from lysine (K) and arginine (R) and  $r$  is preferably 1.

The nature of the amino acid residues  $Xaa$  and  $Xaa^1$  does not seem to be important. It appears that they may be any amino acid residue. However,  $Xaa^1$  is preferably proline  
25 P) or glutamic acid (E).

In even more preferred peptides  $r$  is 1 and at least one of  $m$  and  $n$  is 1.

30 Preferred peptides of the invention comprise the sequence  $(K/R)_{0-1} - K/R - X - K/R$ , wherein  $X$  has the meaning  $Xaa^1$ , suitably the sequence  $K/R - K/R - X - K/R$  or  $K/R - X - K/R$ , more suitably the sequence  $K/R - P - K/R$ ,  $K/R - K/R - P - K/R$ ,  $K/R - K/R - E - K/R$  or  $K/R - K/R - E - K/R$ , even more suitable  $K - P - K$ ,  $K - K - P - K$ ,  
35  $K - K - E - K$  or  $K - K - E - R$  and most suitable the sequences A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q

(SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).

It may be speculated that the reason why the distance between the basic amino acid residues is a variable factor in the deduced motif, is that one of the important properties of the ligand may be the exposure of a cluster of basic amino acid residues, i.e. an epitope comprising basic amino acids residues. Such a cluster may be created by a sequence of closely linked basic amino acids or alternatively through peptide/protein folding. Advantageously, the basic amino acid residues may be exposed on the surface of a carrier. Particularly, multimeric peptides such as dendrimers may form conformational determinants or clusters due to the presence of multiple flexible peptide monomers.

As discussed above, the analysis of the active peptides isolated from the peptide library suggests that the motif may comprise more than two positively charged amino acids, for example three or four basic amino acids. The strength of the binding and of the resulting downstream signal probably depend upon the number and/or the position of the basic amino acids in the peptide, resulting in clusters of variable functional strength. The position of other amino acids in the peptide may be of importance, especially in the case of peptide folding. The variable strength of the cluster may result in variable binding constants and thus in variable strength in signalling.

Without wishing to be bound by a certain theory, the inventors believe that active ligands to the NCAM Ig1 and/or the NCAM Ig2 domain are ligands which bind to the NCAM Ig1 domain and/or the NCAM Ig2 domain thus trigger a conformational change of the domain resulting in a signalling cascade being initiated, which signalling

influences proliferation of cells and/or neurite outgrowth. Thus, a suitable ligand may be any compound which can trigger a conformational change of the NCAM Ig1 domain and the NCAM Ig2 domain, resulting in a downstream signalling.

Very interesting peptides are those which correspond to a part of the NCAM Ig2 domain, are a mimic or fragment of the NCAM Ig2 domain.

10

The peptides may bind to the Ig2 binding site on the NCAM Ig1 domain or to a binding site different from the NCAM Ig2 binding site. It is believed that the ligands C3, D3 and D4 bind to a site different from the binding site of NCAM Ig2 or fragments thereof.

15

Of likewise particular interest in addition to ligands of the Ig1 domain, are ligands of the Ig2 domain including the ligands of that part of the Ig1-Ig2 binding site which is constituted by the Ig2 domain.

20

Other compounds which are interesting compounds for the purposes of the present invention are non-peptide molecules mimicking the binding of the NCAM Ig1, the NCAM Ig2 domain or the artificial ligands. Such other compounds may be selected from small organic compounds, sugars and lipids, as well as peptidomimetics, peptoides and peptomers.

25

Libraries of small organic compounds may be screened to identify artificial ligands of the NCAM Ig1 domain, the NCAM Ig2 domain and artificial ligands of the Ig1-Ig2 binding site, that is constituted by the NCAM Ig1 and Ig2 domains, which ligands may stimulate NCAM activity. Such libraries or their construction are commonly known and the screening for useful ligands may follow the methods

30

35

for screening disclosed in this paper, or in ways obvious to the skilled person.

Such other compound may also be an anti-NCAM Ig1  
5 antibody, an anti-NCAM Ig2 antibody (monoclonal, polyclonal or recombinant) or another antibody recognising epitopes in or near the binding site, that is constituted by the NCAM Ig1 and Ig2 domains, which antibody further may be chimeric or humanised. The  
10 production of polyclonal as well as a) monoclonal anti-NCAM Ig1 antibodies and/or b) anti-NCAM Ig2 antibodies may follow common known procedures. Mice or rabbits may serve as the primary immunisation forum, in which antibodies to NCAM Ig1 or antibodies to NCAM Ig2 are  
15 raised. Purified polyclonal antibodies may be used without any further treatment. Alternatively, monoclonal antibodies may be produced. Methods of producing monoclonal antibodies are common in the art. Recombinant antibodies such as chimeric and humanised antibodies may  
20 also be obtained by methods common in the art. Possible active antibodies are then screened according to the methods disclosed above or in similar ways.

Substances with the potential to promote neurite  
25 outgrowth as well as survival and proliferation of neuronal cells such as certain endogenous trophic factors are prime targets in the search for compounds that facilitate neuronal regeneration and other forms of neuronal plasticity (Fu and Gordon, 1997). Peripheral  
30 nerves possess a potential to regenerate and re-establish functional connections with their targets after various injuries. However, functional recovery is rarely complete and peripheral nerve damage remains a considerable problem. In the central nervous system, the potential for  
35 regeneration is very limited. Therefore, the identification of substances with the ability to promote

functional regeneration in the peripheral and the central nervous system is of great interest. To evaluate the potential of a substance to promote regeneration, the ability to stimulate neurite outgrowth and proliferation and survival of neuronal cells may be investigated. The NCAM Ig1 or NCAM Ig2 binding compounds of the present invention are shown to promote neurite outgrowth and to affect neuronal proliferation and are therefore most likely good promoters of regeneration of neuronal connections and thereby of functional recovery after damages as well as promoters of neuronal function in other conditions where such an effect is required.

Accordingly, the present invention relates to the NCAM Ig1 domain, the NCAM Ig2 domain and a fragment or a mimic thereof for use in the treatment of a normal, degenerated or damaged NCAM presenting cell. An example of a fragment of the NCAM Ig1 domain is the part of the NCAM Ig1 domain which is involved in the NCAM Ig1-Ig2 binding site. In particular, the invention relates to the NCAM Ig2 domain, a fragment or a mimic thereof for use in the treatment of normal, degenerated or damaged NCAM presenting cells, which treatment consists of stimulating outgrowth from and/or proliferation of the NCAM presenting cells.

The treatment may suitably be a treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs such as treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibres, postischaemic, e.g. resulting from a stroke, Parkinson's disease, Alzheimer's disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and

schizophrenia, treatment of diseases of muscles including conditions with impaired function of neuro-muscular connections such as genetic or traumatic atrophic muscle disorders, a treatment of diseases of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel, and treatment or stimulation of the ability to learn and/or of the memory.

10

The present invention also relates to the use of the NCAM Ig1-Ig2 domain and/or the use of that part of the NCAM Ig1 that is involved in the NCAM Ig1-Ig2 binding site, or a fragment of mimic thereof in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells. Thus, the present invention relates to the use of the NCAM Ig2 domain, or a fragment of mimic thereof in the manufacture of a medicament for the treatment of NCAM presenting cells, so as to provide a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.

15

In particular, the use of the NCAM Ig2 domain, or a fragment or mimic thereof in the manufacture of a medicament for the treatment of NCAM presenting cells, wherein the medicament is for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibres, postischaemic, e.g. resulting from a stroke, Parkinson's disease, Alzheimer's disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or conditions of the muscles including conditions with impaired function

25

30

35

of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas  
5 such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, or is for the stimulation of the ability to learn and/or of the memory.

The invention also relates to a pharmaceutical  
10 composition comprising one or more of the compounds as defined above. In particular, the composition of the invention may comprise a compound being the NCAM Ig2 polypeptide, a fragment or a peptide mimic thereof. In a preferred embodiment, the peptides are formulated as  
15 multimers, e.g. bound to carriers. The peptides may suitably be formulated as dendrimers such as four peptides linked to a lysine backbone, or coupled to a polymer carrier, for example a protein carrier, such as BSA. Such formulations are well-known to the person  
20 skilled in the art.

The invention also concerns a method of treating normal, degenerated or damaged NCAM presenting cells *in vitro* or *in vivo*, which method involves administering, *in vitro* or  
25 *in vivo*, an effective amount of one or more of the compounds described above or a composition as described above, so as to provide a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.

30 In the method of the present invention, the treatment is preferably an *in vivo* treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage,  
35 impaired myelination of nerve fibres, postischaemic, e.g. resulting from a stroke, Parkinson's disease, Alzheimer's

disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of  
5 diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or of diseases or conditions of the organs, such as degenerative conditions of the gonads, of  
10 the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart. to the central or peripheral nervous system of a patient in need of treatment, and the method is characterised in that an effective amount of one or more of the compounds  
15 or a composition as defined above is administered to said patient.

Furthermore, the method of the invention may also be such, wherein the treatment leads to regeneration of  
20 nerves. The compounds are in particular used in combination with a prosthetic device such as a prosthetic nerve guide. Thus, in a further aspect, the present invention relates to a prosthetic nerve guide, characterised in that it comprises one or more of the  
25 compounds or the composition defined above. Nerve guides are known in the art.

In a further aspect, the invention relates to a method of stimulating the ability to learn and/or the memory in a  
30 subject, which method involves administering to a subject in need thereof an effective amount of one or more of the compounds as defined above or a composition as defined above.

35 The invention further concerns a medicament for the treatment of diseases and conditions of the central and



peripheral nervous system, of the muscles or of various organs, which medicament comprises an effective amount of one or more of the compounds as defined above or a composition as defined above in combination with pharmaceutically acceptable additives. Such method may suitably be formulated for oral, percutaneous, intramuscular, intracranial, intranasal or pulmonal administration.

10 In yet another embodiment, the present invention relates to a composition for use in the stimulation of learning and/or memory in a subject, which the composition comprises an effective amount of one or more of the compounds defined above or a composition as defined above  
15 in combination with one or more pharmaceutically acceptable additives. Such composition may suitably be formulated for oral, percutaneous, intramuscular, intracranial, intranasal or pulmonal administration.

20 As appears from the above, increased plasticity is believed to be beneficial in the nervous system such as learning and regeneration and in other conditions outside the nervous system involving degenerative NCAM function. The effect of peptides of the present invention were  
25 investigated with respect to regeneration, i.e. axonal outgrowth from isolated superior cervical ganglia. It was found that peptide of the above-identified motif stimulated outgrowth as compared to a control peptide. It seems as if the observed effect is largely influenced by  
30 the dose administered, which presumably is due to the activating of signal transduction pathways by the NCAM Ig1 binding compounds resulting in a bell-shaped dose-response curve for neurite outgrowth (Fig 8 and 13). Thus a similar bell-shaped dose-response curve will be  
35 expected for the effect of NCAM Ig1 binding compounds on neuronal regeneration and other forms of plasticity

dependent on activation of NCAM-mediated signal transduction pathways. The effect of NCAM Ig1 binding compounds on learning could be investigated *in vivo* by intraventricular infusion of the compounds in rodents or other animals followed by examination of the learning abilities of the animals after injections of various doses of NCAM Ig1 binding compounds. Injections should be performed before or at various time points after training as an inhibitory effect of NCAM-antibodies on certain forms of learning has been demonstrated when such injections were performed 5 to 8 hours following training (Scholey et al 1993). Useful learning models for evaluation of the effect of NCAM IG1 binding compounds on learning include passive avoidance and water maze learning in rodents or chicken. The effect of NCAM Ig1 binding compounds on synaptic plasticity associated with learning could be investigated *in vitro* or *in vivo* by measuring the induction or maintenance of long-term potentiation after application of NCAM Ig1 binding compounds, as has been done for NCAM-antibodies (Rønn et al 1995).

Surprisingly, it was found that the NCAM Ig2 domain and NCAM Ig1-binding peptide ligands displaying the characteristics of a motif as indicated above stimulate NCAM mediated signalling. In particular, the C3 peptide, Ig1-p and the Ig2-peptide, Ig2-p, stimulate NCAM functions including neurite extension by interacting with the NCAM Ig1 domain, thereby inducing signal transduction.

Accordingly, the compounds of the present invention are believed to have a beneficial effect in conditions, where which NCAM functions have been shown to be of importance.

As mentioned above, NCAM has been found to be expressed

in several tissues and organs. Thus, interference with NCAM transmembrane signalling may have a beneficial influence in diseases and disorders such as

5 1) Diseases and conditions of the central and peripheral nervous system, in which increased potential for regeneration and synaptic plasticity is desirable such as postoperative nerve-damage; traumatic nerve damage; disorders characterised by impaired myelination of  
10 fibers; postischaemic damage, e.g. resulting from a stroke; Parkinsons disease; Alzheimers disease; other dementias including multiinfarct dementia; Sclerosis; nerve degeneration associated with diabetes mellitus; disorders affecting the circadian clock; disorders  
15 affecting neuro-muscular transmission; and Schizophrenia;

2) Diseases of the muscles including conditions with impaired function of neuro-muscular connections such as genetic atrophic muscle disorders; and traumatic atrophic  
20 muscle disorders;

3) Degenerative conditions of various organs such as degenerative conditions of the gonads; degenerative conditions of the pancreas including disorders involving  
25  $\beta$ -cells; diabetes mellitus type I and II; degenerative conditions of the kidneys such as nephrosis; and degenerative conditions of the heart, liver and bowel.

As mentioned above, the present invention also relates to  
30 medicaments and compositions. Strategies in formulation development of medicaments and compositions based on the compounds of the present invention generally correspond to formulation strategies for any other protein-based drug product. Potential problems and the guidance  
35 required to overcome these problems are dealt with in several textbooks, e.g. "Therapeutic Peptides and Protein

Formulation. Processing and Delivery Systems", Ed. A.K. Banga, Technomic Publishing AG, Basel, 1995.

Injectables are usually prepared either as liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid prior to injection. The preparation may also be emulsified. The active ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, if desired, the preparation may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or which enhance the effectiveness or transportation of the preparation.

Formulations of the compounds of the invention can be prepared by techniques known to the person skilled in the art. The formulations may contain pharmaceutically acceptable carriers and excipients including micropheres, liposomes, microcapsules, nanoparticles or the like.

The preparation may suitably be administered by injection, optionally at the site, where the active ingredient is to exert its effect. Additional formulations which are suitable for other modes of administration include suppositories, nasal, pulmonal and, in some cases, oral formulations. For suppositories, traditional binders and carriers include polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient(s) in the range of from 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine,

cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and generally contain 10-95% of the active ingredient(s), preferably 25-70%.

Other formulations are such suitable for nasal and pulmonal administration, e.g. inhalators and aerosols.

The active compound may be formulated as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide compound) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. Salts formed with the free carboxyl group may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

The preparations are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g. the weight and age of the subject, the disease to be treated and the stage of disease. Suitable dosage ranges are of the order of several hundred  $\mu\text{g}$  active ingredient per administration with a preferred range of from about 0.1  $\mu\text{g}$  to 1000  $\mu\text{g}$ , such as in the range of from about 1  $\mu\text{g}$  to 300  $\mu\text{g}$ , and especially in the range of from about 10  $\mu\text{g}$  to 50  $\mu\text{g}$ . Administration may be performed once or may be followed by subsequently administrations. The dosage with also depend on the route of administration and will vary with the age and weight

of the subject to be treated.

Some of the compounds of the present invention are sufficiently active, but for some of the others, the effect will be enhanced if the preparation further comprises pharmaceutically acceptable additives and/or carriers. Such additives and carriers will be known in the art. In some cases, it will be advantageous to include a compound, which promote delivery of the active substance to its target.

In many instances, it will be necessary to administrate the formulation multiple times. Administration may be a continuous infusion, such as intraventricular infusion or administration in more doses such as more times a day, daily, more times a week, weekly, etc. In connection with the use in nerve guides, the administration may be continuous or in small portions based upon controlled release of the active compound(s). Furthermore, precursors may be used to control the rate of release and/or site of release. Other kinds of implants and well as oral administration may similarly be based upon controlled release and/or the use of precursors.

The treatment needs not be a treatment of an diagnosed disease, but may alternatively be a prophylactic treatment of subjects in general or of subjects known to have a high risk of getting one of the disease discussed above.

The invention is further illustrated by the non-limiting examples.

#### EXAMPLES

35

#### EXAMPLE 1

Preparation of the receptor Ig domain 1 of NCAM

The Ig1 domain of NCAM was produced as a recombinant protein in *Pichia pastoris*. The cDNA fragment encoding amino acids 1-97 of rat NCAM was synthesised by PCR and amplified cDNA was subcloned into an Xho I/Bam HI site of the pHIL-S1 plasmid (Invitrogen Corporation, San Diego, USA). An *E. coli* strain Top 10 F' (Invitrogen Corporation, San Diego, USA) was used for transformation. The recombinant plasmid was linearised with Nsi I and used for transformation of *Pichia pastoris* strain His 4 GS-115 (Invitrogen Corporation, San Diego, USA). Transformation and selection was performed according to a *Pichia* Expression Kit manual supplied by the manufacturer. The recombinant protein was designated as Ig1 PP (Ig-like domain 1 produced in *P. pastoris*). The authenticity of Ig1 PP was secured by amino acid sequencing and MALDI-MS confirming the expected molecular weight of 11 kD. Cells were grown essentially according to the *Pichia* Expression Kit manual. After induction supernatant from growing cells was filtered through a 0.21 mm filter, concentrated by ultrafiltration and purified by gel filtration using a Sephadex G-50 column (Pharmacia Biotech AB, Sweden).

## 25 EXAMPLE 2

Preparation of the Ig domain 2 of NCAM

The cDNA encoding the Ig2 domain of NCAM was synthesised by PCR corresponding to residues 100 to 191. Rat NCAM-120 cDNA was used as template. The amplified cDNA fragment was subcloned into a SnaBI/AvrII site of the pPIC9K plasmid (Invitrogen). The recombinant plasmid was linearised with SacI and used for transformation of *Pichia pastoris* strain His 4 GS-115 (Invitrogen) according to the protocol supplied by the manufacturer. The recombinant Ig2 domain of NCAM was expressed after

induction in a 2 litre fermentor (MBR Mini Bioreactor, MBR Bioreactor AG). Thereafter, the expression medium was concentrated 10 times by ultra-filtration. The Ig2 domain was purified by gel-filtration by means of Sephadex G25 (Pharmacia) followed by ion exchange chromatography using a 5 ml HiTrap SP column (Pharmacia) yielding 10-15 mg per litre of expression medium. The authenticity of the NCAM Ig2 domain was confirmed by amino acid sequencing and mass spectroscopy. In the N-terminal, the original residues Lys-1 and Leu-2 were replaced with Tyr-1 and Val-2 due to cloning site considerations.

The disclosed model of dimerization of the first two domains of NCAM was experimentally demonstrated by the use of a group mutation approach as follows.

The following three mutations were made and the mutated NCAM(20-208) domains were produced as recombinant proteins: NCAM(20-208) with three mutations in the domain-1 E30A, E35A, K37A, NCAM(20-208) with three mutations in the domain-2 R192A, R196A, E198A and NCAM(20-208) with three mutations in the domain-1 E30A, E35A, K37A and three mutations in the domain-2 R192A, R196A, E198A. Mutations in the two sites of interest were introduced by PCR using 75 bp long 5' and 72 bp long 3' primers containing the mutations (5' CTG CAG GTA GAT ATT GTT CCC AGC CAA GGA GCC ATC AGC GTT GGA GCC TCC GCC TTC TTC CTG TGT CAA GTG GCA 3' and 5' ATT CAC AAT GAC CTG AAT GTC CTT GAA GTT GAT GGC CCC GGC GGC CAG GAT GGC GCC CTC ACA GCG GTA AGT 3').

Three mutants of NCAM (20-208) were produced. In the first mutant residues Glu-30, Glu-35 and Lys-37 from the homophilic binding site of domain-1 were substituted with Ala. In the second mutant residues Arg-192, Arg-196 and Glu-198 from the homophilic binding site of domain 2 were substituted with Ala. The third mutant had 6 residues Glu-



30, Glu-35, Lys-37, Arg-192, Arg-196 and Glu-198 substituted with Ala.

Following the confirmation of the presence of mutations by  
5 restriction analysis and DNA sequencing, it was verified  
that there were no significant variations in expression  
levels or in purification patterns for the mutants in  
comparison with the unmutated NCAM(20-208). By the use of  
10 gel filtration chromatography it was revealed that  
NCAM(20-208) elutes as a dimer at ~ 46 kDa, which finding  
provides for offering an easy and reliable way of  
monitoring the effects caused by mutations in the  
homophilic binding site when compared to the finding that  
15 the mutated proteins appeared to elute as a monomer at ~  
23 kDa. Thus, it was demonstrated that the mutations  
abolish the dimer formation, which obviously suggests  
that one or several pairs of the six mutated residues are  
involved in the dimer formation.

20 It was shown by the use of  $^1\text{H}$  NMR spectra of each of the  
three mutated proteins that both domain-1 and domain-2 of  
the mutated double domains are folded very similar to  
folds in the unmodified proteins.

### 25 EXAMPLE 3

#### Synthesis and screening of resin-bound decapeptide libraries

The synthesis of the resin-bound one-bead one-peptide  
30 library was performed using the portioning, mix procedure  
(Furka, Å. et al., (1991) Int. J. Pep. Prot. Res. 37, 487-  
493). Polyethylene syringes served as reaction vessels  
throughout the synthesis and the final TFA-deprotection.  
TentaGel resin (Rapp Polymere, Tübingen, Germany) was  
35 divided into 18 aliquots and the protein L-amino acids  
except cysteine and histidine were used. Side-chains were

protected with the following protecting groups: Asp(tBu), Glu(tBu), Tyr(tBu), Ser(tBu), Thr(tBu), Asn(trt), Gln(trt), Lys(Boc), Trp(Boc), Arg(pmc). Fmoc-protected amino acids (5 eq; Milligen or Novabiochem) were coupled overnight using 5eq DIC and 5eq HOBt. Removal of the Fmoc group was accomplished with 25% piperidine in DMF for 20 min. The side chain protecting groups were removed with 82.5% TFA, 5% anisole, 5% H<sub>2</sub>O, 5% EDT, 2.5% thioanisole at room temperature for 2.5 h followed by washing with tetrahydrofuran and 1% HOAc and the resin was subsequently lyophilised. Screenings were done by incubating 2 ml resin (equivalent to ca. 10<sup>6</sup> beads) with biotinylated receptor in Tris/HCl buffer (Tris/HCl 0.025 M, pH 7.2, 0.25 M NaCl, 0.1 % (w/v) Tween 20) containing 0.1% Gelatin (Sigma) for 60 min. Subsequently the resin was washed in Tris/HCl buffer and incubated with avidin-alkaline phosphatase (diluted 1:20000) for 30 min. The substrates BCIP/NBT (Sigma) were added as described by the procedure by Lam et al. (1992) and stained beads were removed for micro sequencing. The library was screened with the receptor NCAM Ig1-PP (10 mg/ml).

#### EXAMPLE 4

##### 25 Sequencing of beads and selection of peptides to be synthesised

The most intensely stained beads were selected under stereo microscope and sequenced on an ABI 470A equipped with an ABI 120A HPLC. The 22 peptide sequences obtained (SEQ ID NO:1 to SEQ ID NO:22) are shown in Fig. 4A. A conspicuous finding was the high prevalence of the basic amino acids lysine (K) and arginine (R) in these identified NCAM Ig1 binding sequences. Peptide sequences to be synthesised and used in the further investigations were chosen by aligning the obtained sequences and examining these for repeated patterns revealing putative

motifs. Three apparent motifs were identified within the peptides. The first motif was the sequence K/R-K/R-P-K/R-K/R-N/S that was partially conserved in a group of peptides including the C3 peptide as shown in Fig. 4B.

- 5 The second motif was K/R-K/R-E-K/R-X-K/R-K/R found partially conserved in three peptides including D3 (Fig. 4C). The third motif, G-X-K/R-P-K/R, was found in two peptides including D4 (Fig. 4D).

10 EXAMPLE 5

Synthesis of peptides

One peptide, Ig1-p (SEQ ID NO: 26) derived from the sequence of NCAM Ig1 was synthesised as described below.

- 15 In addition, one peptide, Ig2-p (SEQ ID NO: 23) derived from the sequence of NCAM Ig2 was synthesised as described below. From combinatorial libraries 22 NCAM Ig1-binding sequences (SEQ ID NO: 1-22) were identified.

- 20 Three peptides, C3 (SEQ ID NO:1), D3 (SEQ ID NO:2) and D4 (SEQ ID NO:3) were selected for further analysis and synthesised on TentaGel resin with Rink amide linker (p-((R,S)- $\alpha$ -(1-(9H-fluoren-9-yl)-methoxyformamido)-2,4-dimethoxybenzyl)-phenoxyacetic acid (Novabiochem)) using
- 25 Fmoc-protected amino acids (3 eq.). Coupling was performed for >60 min. with TBTU (3 eq.), HOBt (3 eq.) and DIEA (4.5 eq.) in a manual multicolumn apparatus. Fmoc was deprotected with 20% piperidine in DMF for 10 min. Synthesis of peptide dendrimers was accomplished by
- 30 coupling Fmoc-Lys(Fmoc)-OH (Novabiochem) to the linker resin followed by Fmoc-deprotection of the Fmoc group and further coupling of Fmoc-Lys(Fmoc)-OH was performed. After Fmoc-deprotection the synthesis of peptides was performed as above for the monomeric peptides. Peptidyl resins were
- 35 deprotected with TFA 90%, 5% H<sub>2</sub>O, 3% EDT, 2% thioanisole, precipitated in diethyl ether, washed three times in

diethyl ether, solubilised in 5% AcOH and lyophilised. Amino acid analysis was performed using Waters picotag and Waters 501 pump connected to WISP 712. Waters 600E equipped with Waters 996 photodiode array detector was used for analytical and preparative HPLC on C<sub>18</sub> columns (Delta-Pak 100Å 15um, Millipore). MALDI-MS was done on a VG TOF Spec E, Fisions Instrument. The peptides were at least 95% pure as estimated by HPLC.

- 10 To investigate the role of important residues of the Ig2-peptide, Ig2-p, two control peptides, called P2-3S and P2-4S respectively of the sequences GSILASGESNFK (P2-3S) and GSILASGSSNFK (P2-4S) were constructed. In P2-3S (SEQ ID NO: 24), the residues Arg-2, Arg-6 and Ile-9 were substituted with serines corresponding to a mutation of residues Arg-192, Arg-196 and Ile-199 of the NCAM Ig2 domain. In P2-4S (SEQ ID NO: 25), the residues Arg-2, Arg-6, Glu-8 and Ile-9 were substituted with serines corresponding to a mutation of residues Arg-192, Arg-196, Glu-198 and Ile-199 of the NCAM Ig2 domain.

To investigate the role of the individual residues in the C3-sequence, so-called scrambled peptides, comprising the same residues as C3 but in a different sequence, were constructed in the same way (121, 114 and C3scr in Fig. 7). Similarly, scrambled peptides corresponding to the residues in the D3 and D4 sequences were constructed (scrambled D3 and scrambled D4 in Fig. 7). Furthermore, peptides containing the C3-sequence in which basic amino acids (Ks and Rs) were substituted with alanines were constructed (116 - 119 in Fig. 7) to explore the role of these particular amino acids. Likewise, a peptide corresponding to the C3-sequence in which the proline-residue (Xaa<sup>1</sup>) was substituted with an alanine was constructed. To further investigate the role of the basic amino acid residues in C3, a peptide containing the C3-

sequence in which the basic amino acids were modified by acetylation was constructed (C3dacetyl. K(120) in Fig. 7).

5     EXAMPLE 6

Plasmon Surface Resonance Analysis

Real-time biomolecular interaction analysis was performed using a BIAlite instrument (Pharmacia Biosensor AB, Sweden). All experiments were performed at 25°C using Hepes buffered saline (HBS: 10mM Hepes pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% v/v Surfactant P20 (Pharmacia Biosensor, Sweden) as running buffer. The flow rate was 5 ml/min. Dendrimer peptides C3, D3 and D4 (four peptide-  
15 monomers coupled to a backbone consisting of three lysines) were immobilised on a sensor chip CM5 (Pharmacia Biosensor AB, Sweden) using the following procedure: the chip was activated by 10ml 0.05 M N-hydroxysuccinimide, 0.2 M N-ethyl-N'-(dimethylaminopropyl)carbodiimide;  
20 peptides were immobilised using 35 ml peptide solution in HBS at a concentration of 60 µg/ml; finally the chip was blocked by 35 µl 1 M ethanolamine hydrochloride pH 8.5. Binding of Ig1 to dendrimer peptides: 50 ml of Ig1 or Ig1I at the indicated concentrations were applied. The chip was  
25 regenerated by two 5 ml pulses of 5 mM NaOH. Two independent experiments were performed. The results confirmed that C3, D3 and D4 bind to the NCAM Ig1 domain.

EXAMPLE 7

30

Aggregation and neurite outgrowth

1) Influence of NCAM Ig1 binding compounds on NCAM mediated cell adhesion. Hippocampal cells were prepared from rat embryos gestational day 17-19. Cerebellar cells  
35 were prepared from postnatal day 4-7 mice. Cells were grown in a defined medium consisting of DMEM/F12 (Gibco,

BRL) supplemented with N2 (Gibco, BRL) or Neurobasal supplemented with B27 (Gibco, BRL), in both cases supplemented with 20 mM HEPES (Gibco, BRL), 0,4% w/v bovine serum albumin (Sigma) and 100 iU/ml penicillin-streptomycin. Dissociated cells were seeded in 60 well microtiter plates (50.000 in 15 ml per well) essentially as described (Maar et al., 1995). After 24 h, the amount of aggregates were counted. Peptides to be tested were added to the cell suspension immediately before seeding of cells in the microwells. When the NCAM Ig1 binding peptides, C3, D3 and D4 were present during the aggregation of cells, a higher number of cell aggregates resulted when quantified 24 h after seeding of cells. Fig. 5 shows the number of aggregates measured 24 h after seeding of cells in the presence of C3d in the indicated concentrations in  $\mu$ M (concentration calculated with respect to the amount of peptide monomers present on the peptide-dendrimers). The peptide moreover resulted in an increase in the number of neuronal processes formed (Fig. 6). D3- and D4-dendrimer likewise increased the number of aggregates formed after 24 h. Scrambled peptides based on the C3-sequence also inhibited aggregation. The effect of the various peptides tested is shown in Fig 7. To localise the active residues of the C3-peptide, alanine substitutions were carried out. Substituting the proline with an alanine did not change the effect. Likewise, one basic amino acid could be substituted by alanine without a change in effect, thus such a peptide (termed "116" in Fig. 7). In contrast, peptides with two to four alanine substitutions of the basic residues had no effect on aggregation indicating that these basic residues are important for the effect of C3. Similar aggregate cultures were prepared in the presence of C3 as monomer, dendrimer or as BSA-coupled 20-mer. Different forms of the C3 peptide were tested. It was found that monomeric, dendrimeric and BSA-coupled forms of C3 had similar

effects on aggregation. However, the dendrimer of the C3 sequence was the most potent form, presumably due to the ability to link several of the receptor domains. To verify that the receptor was situated in the NCAM Ig1 domain, the cells were incubated with this domain prepared in *Pichia pastoris* as described in Example 1 in solution in a concentration of 5.4 or 54  $\mu\text{g/ml}$ . The presence of the NCAM Ig1 domain abrogated the effect of C3 demonstrating an interference with NCAM-mediated cell adhesion of C3. These experiments show that the here identified NCAM Ig1 binding peptides influence NCAM mediated cell adhesion and thereby increase the number of cell aggregates and neuronal processes formed in cultures of primary neurones grown at high densities.

The effect of the NCAM Ig2 domain and the peptides Ig2-p (SEQ ID NO: 23) and Ig1-p (SEQ ID NO: 26) was tested in hippocampal aggregate cultures prepared as described above. It can be seen that the number of cellular aggregates increased in a dose-dependent manner when cultures were treated with various concentrations of the Ig domain 2. In treated cultures, aggregates were smaller when compared to control cultures, indicating that the Ig domain 2 causes a decrease in intercellular adhesion. The Ig2-peptide also inhibited aggregation of cells. By comparing the effects of the Ig domain 2 and Ig2-peptide, it can be seen that both compounds strongly inhibited aggregation in a concentration-dependent manner. To test whether inhibition of aggregation of hippocampal neurons by the Ig2-peptide was specific, peptides in which several residues involved in the binding of the Ig domain 2 to the Ig domain 1 were substituted with Ser were tested. The peptide P2-3S (SEQ ID NO: 24), in which Arg-2, Arg-6 and Ile-9 were substituted with Ser had no inhibitory effect. An Ig2-peptide, P2-4S (SEQ ID NO: 25), in which additionally Glu-8 was substituted with Ser had only a slight inhibitory effect on aggregation of

hippocampal cells. These results show that amino acid residues in the Ig 2 domain involved in its binding to the Ig domain 1 are important for NCAM mediated intracellular adhesion. We also tested the effect of the Ig1-P peptide in aggregate cultures as described. This peptide also inhibited aggregation of cells showing that the part of the NCAM Ig2 domain contributing to the binding site in the NCAM Ig1-Ig2 domains is important for NCAM mediated intracellular adhesion

10

2) NCAM Ig1 binding compounds promote neurite outgrowth. Hippocampal cells were prepared from rat embryos gestational day 18. 5000 cells/well, corresponding to approximately 4000 cells/cm<sup>2</sup>, were seeded in 8 well LabTek Tissue Culture Chamber Slides with a growth surface of Permanox plastic (NUNC A/S, Denmark) or fibronectin (cocultures) and maintained for 20 h as described in Example 7 (1).

20 For cocultures, neurones were seeded on monolayers of fibroblasts, either L-cells or 3T3 cells with or without NCAM-B expression. Neurones were visualised using immunohistochemical staining for growth associated protein 43 kD (GAP43). Briefly, cells were fixed 30 min in 4% paraformaldehyde in phosphate buffered saline (PBS). The primary antibody was rabbit anti-GAP43 1:100 in PBS with 1% fetal bovine serum(FBS), 0.1% bovine serum albumin (BSA), 50 mM glycine, 0.02% NaN<sub>3</sub>, 2% saponine 1h at room temperature or overnight at 4°C. The second antibody was biotinylated swine-anti-rabbit immunoglobulins 1:100 in PBS with 1% BSA 1h at room temperature. The third "layer" was streptavidine coupled to FITC or horse radish peroxidase (HRP) 1:100 1h at room temperature. Between layers, washings were performed 3X20 min in PBS with 1% BSA. Images of living or stained neurones were captured and analysed by the image analysis program Line Length

35



created at the Protein Laboratory. Putative axons were identified as the longest neurite of each cell. Only neurites longer than 10  $\mu\text{m}$  were considered.

5 Fig. 8 shows the effect of C3 added to cocultures of primary hippocampal neurones on monolayers of fibroblasts stably expressing NCAM-140 (LBN) or monolayers of fibroblasts without NCAM expression (LVN). In this model, NCAM expressed by transfected fibroblasts induce an  
10 increased neurite outgrowth from neurones. The mean length of neurites on NCAM-expressing fibroblasts was longer than the mean length of neurites on fibroblasts without NCAM expression. In the presence of C3, there was no difference between the length of neurites on  
15 fibroblasts with or without NCAM expression showing that C3 binds to NCAM (0.54 or 5.4  $\mu\text{M}$ ) in both cerebellar and hippocampal neurones. When neurones were maintained on fibroblasts without NCAM-expression, neurite extension was stimulated by C3 in similar concentrations when  
20 compared to controls maintained in the absence of C3. This shows that C3 stimulates neurite outgrowth.

To investigate the stimulatory effect on neurite extension, cells were prepared as described and seeded on  
25 a substrate of plastic or fibronectin. Cells were then maintained for 21 h and neurite outgrowth was analysed by computer-assisted image analysis using the program Linelength. The mean length of the longest neurite of each cell was measured for neurites longer than 10  $\mu\text{m}$ . In  
30 addition, the mean number of branchpoints per neurite and the mean number of neurites per cell were determined. NCAM Ig1 binding peptides C3, D3 and D4 were added immediately before seeding the cells. This resulted in an increase in neurite outgrowth. The results for the  
35 measurements of the longest neurite per cell are shown in Fig. 9 and Fig. 10 in which the concentrations are given

in  $\mu\text{M}$ . A similar dose-response relationship was found when measuring the number of neurites per cell and the branching of neurites. Scrambled peptides with similar amino acid composition but altered sequences had similar effects as C3, D3 and D4. The effect on neurite outgrowth of the tested NCAM Ig1 binding peptides and the various control-peptides is shown in fig. 7.

To investigate which properties of the NCAM Ig1 binding peptides were important for the observed neuritogenic effect, peptides corresponding to the C3-sequence, but having alanine substitutions of basic amino acids were tested for their effect on neurite outgrowth (Fig. 11). The length of the longest neurite, the number of neurites per cell and the branching of neurites was strongly stimulated by the C3 peptide ( $0.54 \mu\text{M}$ ). A peptide with a similar sequence apart from one alanine substitution of a basic amino acid had similar effects. In contrast, peptides with two to four alanine substitutions had no effect. To investigate the mechanisms of this effect, the C3 peptide ( $0.54 \mu\text{M}$ ) was added in combination with various compounds known to inhibit NCAM dependent signalling (Fig. 12 and Fig. 13). The following compounds were found to inhibit the stimulatory effect of C3 on neurite extension:  $10 \mu\text{M}$  verapamil ("ve" inhibitor of L-type voltage dependent calcium channels),  $0.27 \mu\text{M}$  omega-conotoxin GVIA ("co" inhibitor of N-type voltage dependent calcium channels),  $1 \mu\text{g/ml}$  pertussis toxin ("pertus" inhibitor of certain G-proteins), an erbstatin analogue ("erb"  $0.2 \mu\text{M}$  inhibitor of certain tyrosine kinases), antibody to an acidbox epitope in fibroblast growth factor receptors (FGF-Rs) ( $1:200$  inhibitor of NCAM-FGF-R binding and signalling), a peptide corresponding to the so-called CAM homology domain (CHD) ( $175 \mu\text{M}$ , inhibitor of NCAM-FGF-R binding and signalling). In addition, the neuritogenic effect of C3 was completely

abrogated by the NCAM Ig1 domain, prepared as described in Example 1, in solution. These results show that C3 stimulates neurite outgrowth by binding to the NCAM Ig1 domain and thereby activating signalling pathways in the  
5 neurone that are sensitive to the above mentioned inhibitor-compounds.

To investigate the endogenous ligand of NCAM Ig1, the NCAM Ig2 domain was prepared in *Pichia pastoris* (see  
10 Example 2) and tested for its effect on neurite outgrowth from primary hippocampal neurones maintained on a substrate of fibronectin. The polypeptide comprising the domain was added to the culture-wells immediate before seeding of cells. Fig. 14 shows the mean length of the  
15 longest neurite measured 21 h after seeding of primary hippocampal neurones in the presence of NCAM Ig2 polypeptide ("pLoop2") in the indicated concentrations. It shows that NCAM Ig2 stimulates neurite outgrowth with a bell-shaped dose-response relationship similar to that  
20 of the C3 peptide. The maximal neuritogenic effect of NCAM Ig2 was found at a concentration of 5.4  $\mu\text{g/ml}$  which corresponds to 0.54  $\mu\text{M}$  of the domain. This is the same concentration at which the C3 peptide had a maximal neuritogenic effect. The NCAM Ig2 domain was then tested  
25 in combination with compounds known to inhibit NCAM dependent signalling as described for C3 above. These compounds also inhibited the neuritogenic effect of NCAM Ig2. Thus, NCAM Ig2 and C3 both binds to NCAM Ig1 and both NCAM Ig2 and C3 stimulate neurite extension by  
30 activating identical signal transduction pathways. Therefore, NCAM Ig2 and C3 were tested for their effect on neurite outgrowth when added in combination. The effect of NCAM Ig2 was found to be non-additive to that of C3 (Fig. 15). The results shown that NCAM Ig2 and C3  
35 stimulate neurite extension by identical mechanisms. They both bind the NCAM Ig1 domain and thereby activate

identical signalling pathways leading to neurite outgrowth.

It was shown that the Ig domain 2 and a peptide encompassing residues 191-202 of the Ig domain 2 had a direct effect on neurite outgrowth. Hippocampal cells were grown at a low density and treated with various concentrations of the compounds as described above. To measure neurite outgrowth from hippocampal neurons a simple procedure based on stereological principles was used. Briefly, by means of the software package "ProcessLength" (Protein Laboratory, University of Copenhagen) an unbiased counting frame containing a grid with a certain number of test-lines was superimposed on images of the cell cultures. The number of intersections of cellular processes with the test-lines was counted and related to the number of cell bodies, thereby allowing quantification of the total neurite length per cell. Both the Ig domain 2 and the Ig-peptide strongly stimulated neurite outgrowth from hippocampal neurons in a dose dependent manner. Substitution of either three or four residues with Ser in the Ig2-p as described abrogated the ability of the Ig2-peptide to stimulate neurite outgrowth. In order to increase potency of the Ig2-peptide, we synthesized a dendrimer (Ig2-pd) composed of four monomers coupled to a lysine backbone. The dendrimer had a strong neuritogenic effect with a bell shaped dose-response relationship within the same range of concentrations as it was found for the stimulatory effect of the Ig domain 2. It was observed that in hippocampal cultures treated with the dendrimer at the optimal concentration 3.6  $\mu$ M, neurons exhibited a much higher extend of morphological differentiation than did controls. Thus, we identified an NCAM-derived peptide ligand with a strong neuritogenic activity. Peptides, in which several residues corresponding to those involved in the binding of the Ig domain 2 to the Ig domain 1 were

substituted with Ser, were tested. The peptide P2-3S, in which Arg-2, Arg-6 and Ile-9 were substituted with Ser had no stimulatory effect. An Ig2-peptide, P2-4S, in which additionally Glu-8 was substituted with Ser  
5 likewise had no stimulatory effect on neurite outgrowth from hippocampal cells. Thus these residues are important for the neuritogenic effect of the Ig2-p peptide. Accordingly, the residues Arg-192, Arg-196, Glu-198 and Ile-199 can be considered to be important for the  
10 neuritogenic effect of the NCAM Ig2 domain.

Moreover, hippocampal cell cultures were grown in the presence of the Ig2-p peptide and the first Ig domain. It was seen that the addition of the Ig domain 1 caused a  
15 decrease in the neuritogenic activity of the Ig2-peptide. In addition, antibodies against FGFR, CAM homology domain (CHD) of the receptor and a specific inhibitor of phospholipaseC- $\gamma$  (PLC $\gamma$ ) was demonstrated to inhibit neurite outgrowth induced by the Ig2-p peptide. Indeed,  
20 both anti-FGFR and CHD inhibited, while U-73122, the inhibitor of PLC $\gamma$ , completely abrogated Ig2-peptide induced neurite outgrowth. These data show that the Ig2-peptide stimulates neurite outgrowth through the NCAM-FGFR signalling pathway.

25 The Ig1-p peptide was further shown to promote neurite outgrowth in hippocampal cell cultures prepared as described above. This shows that a sequence corresponding to the part of the Ig1 domain involved in the NCAM Ig1-Ig2 binding can directly stimulate neurite outgrowth.  
30

We additionally tested whether mutations in these residues change the activity of the Ig domain 1-2 with regard to neurite outgrowth. It was seen that the normal  
35 Ig domain 1-2 (Ig1-2) had only slight, if any, effect on neurite outgrowth, which is not surprising since in a dimer all potentially binding sites are blocked. In the

presence of the mutated double domain, extension of neurites from hippocampal cells was inhibited in a dose dependent manner. We therefore conclude that the residues potentially involved in the binding between the first two  
5 Ig domains are important for NCAM-mediated neurite outgrowth.

#### EXAMPLE 8

##### 10 Proliferation

Cell proliferation was determined by incorporation of 5-bromo-2'-deoxyuridin in a cell proliferation ELISA system (Amersham Life Science) according to the procedure of the manufacturer. Primary hippocampal neurones were seeded in  
15 microtiter plates at a density of 33000 cells per well. In the presence of C3d in a concentration of 0.8  $\mu$ M, an increased incorporation of BrdU was observed indicating a stimulation of neuronal proliferation. The dose-response curve was bell-shaped (Fig. 16), thus at higher  
20 concentrations, C3 inhibited proliferation. C3 also promoted proliferation of neuroblastoma cells. However, the net effect on proliferation depended on the growth status of cell. Hence in PC12 cells, an inhibitory effect on proliferation was observed concomitant with an  
25 increased neurite outgrowth indicating that the peptide stimulated differentiation of these cells. These results show that NCAM Ig1 binding compounds can influence proliferation of neurones. The net effect depends on the growth status of the cells but under the proper  
30 circumstances, a stimulation of proliferation will result.

#### EXAMPLE 9

##### 35 Cell growth

Cell growth is another way of monitoring proliferation of

the cells. Primary hippocampal cells were seeded into 96 well microtiter culture plates (Nunc A/S) at a density of 20.000 or 40.000 per well in defined medium as described above. Cells were grown for 48 h, centrifuged in order to  
5 remove medium, fixed in 3.7% formaldehyde in PBS for 15 min and stained with 0.5% Cristal Violet in 20 % methanol for 15 min. Stained cells were thoroughly washed with Milli Q purified water, thereafter residual dye was solubilised with 0.1 M sodium citrate in 50% ethanol pH  
10 4.2 and absorbance measured at 550 nm. When added in 0.8  $\mu$ M immediately preceding seeding of cells, C3 was shown to increase cell growth.

#### EXAMPLE 10

15

##### Structure determination of the NCAM Ig1-Ig2 binding site

By means of the NMR spectra of the two domains of NCAM and their known three-dimensional structures, it was possible to locate the residues that form the binding  
20 sites on the surfaces of the two domains. In the  $^{15}\text{N}$ -HSQC spectrum of  $^{15}\text{N}$  labeled protein a signal for each amino acid residue with both a peptide nitrogen and proton can be observed. The determination of changes in chemical shifts of the signals is therefore a method to locate the  
25 sites in the protein that are perturbed for instance by the binding of another molecule. To the  $^{15}\text{N}$  labeled sample of domain-1 of NCAM unlabelled domain-2 was added to make an excess of two to one in domain-2. The corresponding experiment was performed with the  $^{15}\text{N}$   
30 labeled domain-2 of NCAM. The recorded changes in  $^1\text{H}$  and  $^{15}\text{N}$  chemical shifts for each residue were mapped onto the structures of domain-1 and domain-2, respectively using a cut-off at 0.04 ppm and 0.2 ppm, respectively for the perturbed  $^1\text{H}$  and  $^{15}\text{N}$  chemical shift. The residues that  
35 experience high chemical shift-perturbation in domain-1 are Gly-12, Gly-17, Glu-18, Ser-19, Lys-20, Phe-22, Cys-24, Arg-51, Leu-64, Ile-66, Tyr-67, Ala-69, Ile-71, Asn-

94 and Lys-96, and in domain-2 the residues are Thr-131, Ile-132, Glu-173, Gly-174, Ile-176, Leu-177, Ala-178, Gly-180, Glu-181, Ile-182, Asn-183 and Phe-184. The chemical shift changes of the peptide backbone NMR  
5 signals for these residues in the two domains report, that the presence of the other NCAM domain is changing the chemical environment at these sites, suggesting that the other NCAM domain is binding in the neighborhood of these.

10

The mapping of the residues perturbed by the addition of the other domain show very clearly that these residues are located in one well-defined and coherent patch on each of the domain surfaces. This is a good indication  
15 that the two patches of residues on the surface are either parts of or in the neighborhood of the binding site for the interaction between the two domains.

Three samples were used in the structure determination,  
20 (a) unlabeled NCAM domain-2 in H<sub>2</sub>O, ~1mM, (b) unlabelled NCAM domain-2 in D<sub>2</sub>O, ~1mM, and (c) <sup>15</sup>N-labeled NCAM domain-2 in H<sub>2</sub>O, ~1mM. In all cases the buffer was 50 mM NaCl, 20 mM potassium phosphate pH 6.0. The following NMR spectra were recorded of NCAM domain-2 and used for  
25 assignment: TOCSY, respectively, in H<sub>2</sub>O and in D<sub>2</sub>O both using a mixing time of 70 ms; DQFCOSY, respectively, in H<sub>2</sub>O and in D<sub>2</sub>O; NOESY, respectively in H<sub>2</sub>O and in D<sub>2</sub>O using either a mixing time of 100 ms or of 200 ms; a <sup>15</sup>N HSQC; a <sup>15</sup>N TOCSY-HSQC with a mixing time of 70 ms; and  
30 a <sup>15</sup>N NOESY-HSQC with a mixing time of 100 ms. The NMR experiments were performed on a Bruker AMX-600 MHz spectrometer and on a Varian Unity Inova 750 MHz spectrometer. All spectra were recorded at 298 K. The assignment of the <sup>1</sup>H and <sup>15</sup>N resonance lines from these  
35 spectra were performed using the computer program PRONTO. For structure calculations a distance geometry/simulated annealing protocol from X-PLOR was used. 100 structures were calculated, and 70 structures were accepted by X-



PLOR, discriminating any structure with a NOE-violation > 0.5 Å and/or an angle-violation > 5°. Of these 70 structures the 20 structures with lowest energy were chosen to represent the structure of NCAM domain-2. The structure calculations used 107 intra-, 300 sequential-, 145 short- range- and 466 long range-NOEs derived from 2D-NOESY and <sup>15</sup>N NOESY-HSQC spectra, with upper bounds of 2.7, 3.3, 4.3 and 5 Å. These were increased by 0.5 Å when the NOE restraint included a methyl group. 41 ϕ dihedral angle restraints were applied with bounds of -120 ±40° and -57 ±40°, respectively, when the <sup>3</sup>J<sub>HNHα</sub> coupling constant derived from the DQFCOSY and the NOESY spectra were > 8 Hz or < 5 Hz, respectively. 34 χ<sup>1</sup> dihedral angles were assigned by estimates of the <sup>3</sup>J<sub>HαHβ</sub> coupling constants and the NOE intensities from the DQFCOSY and the NOESY spectra, respectively. In the final structure calculations 78 hydrogen bond restraints were selected and applied as NOE restraints into the calculations with upper bounds of 2.1 Å for the H<sup>N</sup>-O distance and 3 Å for the N-O distance. The structures of NCAM domain-2 were examined using the program PROCHECK\_NMR. The elements of secondary structure were identified using MOLMOL and PROCHECK\_NMR. For the binding studies of domain-1 and domain-2 six <sup>15</sup>N HSQC spectra of the following samples were recorded: a) <sup>15</sup>N-HSQC of <sup>15</sup>N-labeled domain-1 (1 mM and 0.5 mM); b) <sup>15</sup>N-HSQC of <sup>15</sup>N-labeled domain-2 (1 mM and 0.5 mM); c) <sup>15</sup>N-HSQC of <sup>15</sup>N-labeled domain-1 added unlabeled domain-2 (ratio 0.5 mM:1mM); d) <sup>15</sup>N-HSQC of <sup>15</sup>N-labeled domain-2 added unlabeled domain-1 (ratio 0.5 mM:1mM). The titrations of domain-1 to domain-2 were performed recording the chemical shift changes in the <sup>15</sup>N HSQC spectra. All samples were measured at pH 6.0 and 298 K, 50 mM NaCl and 20 mM potassium phosphate. The NMR experiments were performed on a Varian Unity Inova 750 MHz spectrometer. Analysis of the spectra was performed using PRONTO. The affinity of the binding between domain-1 and domain-2, was determined in a titration experiment

where  $^{15}\text{N}$  labeled domain-2 was titrated with unlabeled domain-1. In a 14-point titration with unlabeled domain-1 the change of chemical shifts was measured for 10 residues. Fitting of the binding curves for each of these 10 residues resulted in the same dissociation constant  $K_d$  of  $(2.5 \pm 2) \times 10^{-3}$  M. The coherence of the patches of residues perturbed on the surfaces of the two NCAM domains as well as the identical binding constants measured for the perturbed sites in domain-1 all suggest that the binding is very specific although weak under the conditions of the NMR measurements. The titration was performed adding aliquots of a 2:1 mixture of unlabelled domain-1 (2mM) and  $^{15}\text{N}$  labeled domain-2 (1mM) to a 1mM solution of  $^{15}\text{N}$  labeled domain-2. In this way the concentration of  $^{15}\text{N}$  labeled domain-2 was maintained at 1.0 mM, and the concentration of domain-1 was gradually increased. Protein concentrations were determined by amino acid analysis. Fitting of the titration points to a binding curve of a two-component interaction was performed using the program CANOO. For model building of the dimer of the first two domains of NCAM, (Ig1-Ig2) a distance geometry/simulated annealing - and restrained dynamic - protocol from X-PLOR was used. As restraints were used the restraints obtained from NOE and coupling constant measurements of domains-1 and -2. The proposed intermolecular salt bridges were built into the model as hydrogen bond restraints and applied as NOE restraints into the calculations with upper bounds of 2.1 Å for the  $\text{H}^{\text{N}}\text{-O}$  distance and 3Å for the  $\text{N-O}$  distance. Twenty structures were calculated and ten of these structures with the lowest energy were selected for the evaluation of the model building of (Ig1-Ig2) of NCAM.

## References

- Andersson AM. Biochemical Journal 1993; 290:641-8.
- 5 Beggs, H.E. N Journal of Biological Chemistry 1997, 272,  
no. 13: 8310-8319.
- Carenini S. Cell & Tissue Research 1997; 287:3-9.
- Cremer H Molecular & Cellular Neurosciences 1997;  
8:323-35.
- 10 Cremer H. Nature 1994; 367:455-9.
- Daniloff JK. Journal of Cell Biology 1986; 103:929-45.
- Daston MM. Journal of Neuroscience 1996; 16:5488-97.
- Doherty P. Nature 1992; 356:791-3.
- Doherty P. Molecular and Cellular Neuroscience 1996;  
15 8:99-111.
- Doyle E. Journal of Neuroscience Research 1992;  
31:513-23.
- Edelman GM Cold Spring Harbor Symposia on Quantitative  
Biology. Cold Spring Harbor Laboratory Press, 1990:  
20 303-18.
- Fazeli S. Seminars in the Neurosciences 1997; 8:367-77.
- Fields RD. Trends in Neurosciences 1996; 19:473-80.
- Frei T. Journal of Cell Biology 1992; 118:177-94.
- Furka, A. International Journal of Peptide & Protein  
25 Research 1991; 37: 487-493.
- Gaardsvoll H. European Journal of Cell Biology 1993;  
61:100-7.
- Horstkorte R. The Journal of Cell Biology 1993; 121, no  
6:1409-21.
- 30 Jucker M. Brain Research 1995; Molecular Brain  
Rese:149-56.
- Kasper C. Journal of Neuroscience Research 1996;  
46:173-86.
- Kiselyov V. Journal of Biological Chemistry 1997, 272:  
35 10125-10134.

- Knittel T. American Journal of Pathology 1996;  
149:449-62.
- Krushel LA. Proceedings of the National Academy of  
Sciences of the United States of America 1998; 95:2592-6.
- 5 Lackie PM. Development 1990; 110:933-47.
- Lahrtz F. Journal of Neuroscience Research 1997;  
50:62-8.
- Lam, KS. Nature 1991, 354: 82-84.
- Lam, KS. Immunomethods 1992, 1, 11-15.
- 10 Landmesser L. Neurone 1990; 4:655-67.
- Luthi A. Nature 1994; 372:777-9.
- Maar, TE. Journal of Neuroscience Research 1997, 47:  
163-172.
- Massaro AR. Italian Journal of Neurological Sciences  
15 1987; Suppl 6:85-8.
- Moller CJ. Anatomy & Embryology 1991; 184:541-8.
- Moller CJ. Molecular Endocrinology 1992; 6:1332-42.
- Nieke J. Differentiation 1985; 30:141-51.
- Olsen M. Int J Devl Neuroscience 1995; 13:97-104.
- 20 Ono K. Neurone 1994; 13:595-609.
- Pollerberg GE. Developmental Biology 1993; 156(2):324-40.
- Rabinowitz JE. Proceedings of the National Academy of  
Sciences of the United States of America 1996; 93:6421-4.
- Ranheim, T.S. Proceedings of the National Academy of  
25 Sciences of the United States of America 1996, 93: 4071-  
4075.
- Rao Y. Journal of Cell Biology 1992; 118:937-49.
- Rao Y. Journal of Biological Chemistry 1994;  
269:27540-8.
- 30 Romanska HM, Journal of Pediatric Gastroenterology &  
Nutrition 1996; 22:351-8.
- Rønn LC. Brain Research 1995; 677:145-51.
- Rønn LC. Ph.D.thesis; The Protein Laboratory and The  
Division of Neurophysiology, University of Copenhagen  
35 1997.
- Rutishauser U. Trends in Neurosciences 1996; 19:422-7.

- Sandig M. Journal of Biological Chemistry 1994;  
269:14841-8.
- Sanes JR. Journal of Cell Biology 1986; 102:420-31.
- Schmid R-S. Journal of Neurobiology 1999; 38:542-558.
- 5 Scholey AB. Neuroscience 1993; 55:499-509.
- Schuch U. Neurone 1989; 3:13-20.
- Shen H. Journal of Neuroscience 1997; 17:5221-9.
- Stahlhut M. Journal of Neuroscience Research 1997;  
48:112-21.
- 10 Stork O. European Journal of Neuroscience 1997;  
9:1117-25.
- Thomsen NK. Nature Structural Biology 1996; 3:581-5.
- van Kammen DP. Biological Psychiatry 1998; 43:680-6.
- Walsh FS. Neuroscience Letters 1985; 59:73-8.
- 15 Zhang H. Journal of Neuroscience 1992; 12:3107-14.

## CLAIMS

- 1 A compound which binds to the NCAM Ig1-Ig2 domains  
and is capable of stimulating or promoting neurite  
5 outgrowth from NCAM presenting cells and/or  
proliferation hereof.
- 2 A compound according to claim 1 which binds to the  
NCAM Ig1 domain.
- 10 3 A compound according to claim 1 which binds to the  
NCAM Ig2 domain.
- 4 A compound according to claim 1 or 2 which binds to  
15 the homophilic binding site of the Ig1-Ig2 domains  
which is constituted by the Ig1 domain.
- 5 A compound according to claim 1 or 3 which binds to  
the homophilic binding site of the Ig1-Ig2 domains  
20 which is constituted by the Ig2 domain.
- 6 A compound according to any of the claims 1, 2 or 4  
which compound is the NCAM Ig2 polypeptide or a  
fragment or a mimic hereof.
- 25 7 A compound according to claim 6 which compound is the  
NCAM Ig2 polypeptide.
- 8 A compound according to claim 6 which compound is a  
30 fragment or a mimic of the NCAM Ig2 polypeptide.
- 9 A compound according to claim 1, 3 or 5 which  
compound is the NCAM Ig1 polypeptide or a fragment or  
a mimic hereof.

35

- 10 A compound according to claim 9 which compound is the NCAM Ig1 polypeptide.
- 5 11. A compound according to claim 9 which compound is a fragment or a mimic of the NCAM Ig1 polypeptide.
- 10 12. A compound of any of claims 6-8 which compound is a peptide which binds to the NCAM Ig1 domain through a binding motif which comprises at least 2 basic amino acid residues.
- 15 13. A peptide of claim 12 which comprises at least 2 basic amino acid residues within a sequence of 10 amino acid residues.
- 20 14. A peptide of claim 13 which comprises at least 2 basic amino acid residues within a sequence of 3 amino acid residues.
- 25 15. A peptide of any of claims 6-8 or 12-14, characterised in that it comprises the sequence:  
$$(Xaa^+)_{m} - (Xaa)_{p} - (Xaa^+) - (Xaa^1)_{r} - (Xaa^+) - (Xaa)_{q} - (Xaa^+)_{n},$$
  
wherein  $Xaa^+$  is a basic amino acid residue,  
 $Xaa^1$  is any amino acid residue,  
 $Xaa$  is any amino acid residue, and  
 $m, n, p, q$  and  $r$  independently are 0 or 1.
- 30 16. A peptide according to any of claims 12-15 wherein the basic amino acid residues are lysine (K) or arginine (R).
- 35 17. A peptide according to any of claims 12-16 wherein  $r$  is 1.

18. A peptide according to claim 17 wherein Xaa<sup>1</sup> is proline (P) or glutamic acid (E).
19. A peptide according to any of claims 12-18 wherein at  
5 least one of m and n is 1.
20. A peptide according to claims 12-19 wherein the peptide comprises the sequence (K/R)<sub>0-1</sub>-K/R-X-K/R), wherein X has the meaning Xaa<sup>1</sup>, suitably the sequence  
10 K/R-K/R-X-K/R or K/R-X-K/R, more suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-E-K/R or K/R-K/R-E-K/R, even more suitably the sequence K-P-K, K-K-P-K, K-K-E-K or K-K-E-R and most suitably the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-  
15 E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
21. A peptide according to claim 20 which peptide has the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-  
20 E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
22. A peptide according to any of claims 12-21 wherein one or more of the amino acid residues is modified,  
25 such as being acetylated.
23. A peptide according to any of the claims 12-22, which peptide is identical to a part of the NCAM Ig2 domain.  
30
24. A peptide according to any of the claims 12-22, which peptide is a mimic of the NCAM Ig2 domain or of a fragment of the NCAM Ig2 domain.

35



25. A peptide according to any of claims 12-24, which peptide binds to the NCAM Ig2 binding site on the NCAM Ig1 domain.
- 5 26. A peptide according to any of claims 12-24, which peptide binds to a binding site on the NCAM Ig1 domain, which binding site is different from the NCAM Ig2 binding site.
- 10 27. A compound according to any of the claims 6-8, which compound is a non-peptide molecule mimicking binding to the Ig1 domain of the NCAM Ig2 domain or a fragment thereof or a peptide mimic thereof.
- 15 28. A compound according to any of the claims 6-8, which compound is an anti-NCAM Ig1 antibody.
29. An antibody according to claim 28, which antibody is monoclonal.
- 20 30. An antibody according to any of claims 28-29, which antibody is chimeric or humanised.
- 25 31. A compound according to any of the claims 2 and 4 which compound is a peptide, where the binding motif comprises at least 2 basic amino acid residues and at least 1 apolar amino acid.
- 30 32. A peptide according to claim 31 where the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.
- 35 33 A peptide according to any of the claims 31 and 32 where the number of amino acid residues in the sequence of the binding motif is within 8 amino acid residues.

34 A peptide of any of the claims 2,4,31,32 and 33,  
characterised in that it comprises the sequence:  
(Xaa<sup>+</sup>) - (Xaa) - (Xaa) - (Xaa)<sub>m</sub> - (Xaa<sup>+</sup>) - (Xaa) - (Xaa<sup>-</sup>)<sub>n</sub> - (Xaa<sup>h</sup>) -  
5 (Xaa)<sub>o</sub> - (Xaa<sup>h</sup>)<sub>p</sub>,

wherein Xaa<sup>+</sup> is a basic amino acid residue, Xaa<sup>-</sup> is a  
an acidic amino acid residue, Xaa<sup>h</sup> is a apolar amino  
acid residue, Xaa is any amino acid residue, and  
10 m,n,o and p independently are 0 or 1.

35 A peptide according to any of the claims 31-34,  
wherein the basic amino acid residues preferably are  
lysine (K) or arginine (R).

15

36 A peptide according to any of the claims 31-34,  
wherein the the acidic amino acids preferably are  
glutamic acid (E) or aspartic acid (D), the apolar  
amino acids are preferably leucine (L), isoleucine  
20 (I), valine (V) or phenylalanine (F), and r  
preferably is 1.

37 A peptide according to claims 31-36 wherein the  
peptide comprises the sequence (K/R)-X-X-X-(K/R)-X-  
25 (E/D)-(L/I/V/F)-X-(L/I/V/F), wherein X is any amino  
acid residue, suitably the sequence (K/R)-X-(E/D)-  
(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(E/D),  
(K/R)-X-X-(K/R)-X-(E/D) or (K/R)-X-(L/I/V/F)-X-  
(L/I/V/F), more suitably the sequences (K/R)-X-X-X-  
30 (K/R)-X-(E/D)-(L/I/V/F), (K/R)-X-X-(K/R)-X-(E/D)-  
(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(L/I/V/F), even more  
suitably the sequences (K/R)-X-X-(K/R)-X-(E/D)-  
(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(L/I/V/F)-  
X-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F)-  
35 (L/I/V/F) and most suitably the sequence GRILARGEINFK  
(SEQ ID NO: 23).

- 38 A peptide according to claims 37 wherein the peptide has the sequence GRILARGEINFK (SEQ ID NO:23).
- 5 39. A peptide according to any of claims 31-38 wherein one or more of the amino acid residues is modified, such as being acetylated.
- 10 40. A peptide according to any of the claims 31-39, which peptide is a mimic of, is a fragment of or is identical to a part of the homophilic binding site of the NCAM Ig1-Ig2 domains which is constituted by the Ig2 domain.
- 15 41. A non-peptide according to any of the claims 2 and 4.
42. A compound according to claims 4, which compound is an antibody against the Ig1 domain.
- 20 43. An antibody according to claim 42, which antibody is monoclonal.
44. An antibody according to any of claims 42-43, which antibody is chimeric or humanised.
- 25 45. A compound according to any of the claims 3 and 5 which compound is a peptide, where the binding motif comprises at least 2 acidic amino acid residues and at least 1 apolar amino acid.
- 30 46. A peptide according to claim 45 where the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.

- 47 A peptide according to claim 46 where the number of amino acid residues in the sequence of the binding motif is within 9 amino acid residues.
- 5 48 A peptide according to any of the claims 3, 5, 45, 46 and 47, characterised in that it comprises the sequence:
- 10  $(Xaa^-) - (Xaa) - (Xaa) - (Xaa)_m - (Xaa^+) - (Xaa^-) - (Xaa^-) - (Xaa^h) - (Xaa^h)_p,$
- wherein  $Xaa^+$  is a basic amino acid residue,  $Xaa^-$  is an acidic amino acid residue,  $Xaa^h$  is an apolar amino acid residue,  $Xaa$  is any amino acid residue, and
- 15  $m, n, o$  and  $p$  independently are 0 or 1.
- 49 A peptide according to any of the claims 45-48, wherein the basic amino acid residues preferably are lysine (K) or arginine (R).
- 20 50 A peptide according to any of the claims 45-48, wherein the the acidic amino acids preferably are glutamic acid (E) or aspartic acid (D), the apolar amino acids are preferably leucine (L), isoleucine (I), valine (V) or phenylalanine (F), and  $r$
- 25 preferably is 1.
- 51 A peptide according to claims 45-50 wherein the peptide comprises the sequence  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$ , wherein  $X$  is any amino acid residue, suitably the sequence  $(E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$ ,  $(E/D) - X - (K/R) - (L/I/V/F) - (L/I/V/F)$ ,  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F)$ ,  $(E/D) - X - X - X - (E/D) - X - (K/R) - (L/I/V/F)$  or  $(E/D) - X - X - (E/D) - X - (K/R) - (L/I/V/F)$ , more suitably  $E/D) - X - X - (E/D) - X - (K/R) - (L/I/V/F) - X - (L/I/V/F)$  or  $(E/D) - X - X -$
- 30
- 35

(E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F), even more suitably  
the sequences  
(E/D) -X-X-X-X- (E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F),  
(E/D-X-X-X- (E/D) -X- (K/R) - (L/I/V/F) -X- (L/I/V/F) or  
5 (E/D) -X-X-X- (E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F), and  
most suitably the sequence GEJSVGESKFFL (SEQ ID NO:  
26).

10 52 A peptide according to claims 51 wherein the peptide  
has the sequence GEJSVGESKFFL (SEQ ID NO: 26).

15 53. A peptide according to any of claims 45-52 wherein  
one or more of the amino acid residues is modified,  
such as being acetylated.

20 54. A peptide according to any of the claims 45-53, which  
peptide is a mimic of a part of the homophilic  
binding site of the NCAM Ig1-Ig2 domains which is  
constituted by the Ig1 domain.

25 55. A non-peptide according to any of the claims 3 and 5.

56. A compound according to any of the claims 3 and 5,  
which compound is an antibody against the Ig2 domain.

25 57. An antibody according to claim 56, which antibody is  
monoclonal.

30 58. An antibody according to any of claims 56-57, which  
antibody is chimeric or humanised.

35 59. A compound according to any of the claims 1-58 or a  
fragment hereof or a mimic hereof for use in a  
treatment of normal, degenerated or damaged NCAM  
presenting cells.

60. A compound according to any of the claims 1-58, for use in a treatment, which consists of stimulation of outgrowth from and/or proliferation of the NCAM presenting cells.

5

61. A compound according to any of the claims 1-60 for use in a treatment according to any of the claims 59-60 wherein the treatment is a treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs.

10

62. A compound according to any of the claims 1-61 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia.

15

20

63. A compound according to any of the claims 1-62 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases of muscles including conditions with impaired function of neuro-muscular connections such as genetic or traumatic atrophic muscle disorders.

25

30

64. A compound according to any of the claims 1-62 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus

35

type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

- 5 65. A compound according to any of the claims 1-62 for use in a treatment according to any of the claims 59-60 wherein the treatment is a stimulation of ability to learn and/or of the memory.
- 10 66. Use of a compound according to any of the claims 1-58 in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells.
- 15 67. Use according to claim 66 wherein the treatment is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.
- 20 68. Use according to any of claims 66-67 wherein the medicament is for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct
- 25 dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or conditions of the muscles including conditions with
- 30 impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus
- 35 type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

69. Use according to any of claims 66-67 wherein the medicament is for the stimulation of the ability to learn and/or of the memory.
- 5
70. A pharmaceutical composition comprising one or more of the compounds according to any of the claims 1-58.
- 10
71. A composition according to claim 70 wherein the compound is the NCAM Ig1 peptide or a fragment or a mimic thereof.
- 15
72. A composition according to claim 70 wherein the compound is the NCAM Ig2 peptide or a fragment or a mimic thereof.
- 20
73. A composition according to any of the claims 70-72 wherein the peptides are formulated as multimers.
- 25
74. A composition according to any of the claims 70-73, characterised in that the peptides are formulated as dendrimers, such as four peptides linked to a lysine backbone, or coupled to a protein carrier such as BSA.
- 30
75. A method of treating normal, degenerated or damaged NCAM presenting cells *in vitro* or *in vivo*, characterised in that an effective amount of one or more of the peptides according to any of the claims 1-58 or a pharmaceutical composition according to any of the claims 70-74 is administered *in vitro* or *in vivo*.
- 35
76. A method according to claim 75 wherein the treatment is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.



- 5 77. A method of any of claims 75-76 wherein the treatment is an *in vivo* treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or of diseases or conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.
- 10 78. A method according to any of claims 75-76 wherein the treatment leads to regeneration of nerves.
- 15 79. A method according to claim 78 wherein the compounds are used in combination with a prosthetic device.
- 20 80. A method according to claim 79 wherein the device is a prosthetic nerve guide.
- 25 81. A prosthetic nerve guide, characterised in that it comprises one or more of the compounds according to any of the claims 1-81 or a composition according to any of the claims 71-74.
- 30 82. Method of stimulating the ability to learn and/or the memory in a subject, characterised in that an

effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 71-74 is administered to said subject.

5

83. Medicament for the treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs, characterised in that the medicament comprises an effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 70-74 and one or more pharmaceutically acceptable additives or carriers.

10  
15 84. A medicament according to claim 83 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.

20 85. A pharmaceutical composition for use in the stimulation of learning and/or memory in a subject, characterised in that the composition comprises an effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 70-74 and one or more pharmaceutically acceptable additives or carriers.

25

86. A composition according to claim 85 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.

30

1/25

Different forms of the neural cell adhesion molecule (NCAM).




FIG. 1

2/25

Identification of synthetic peptide ligands of the NCAM Ig1 domain by means of combinatorial peptide-libraries.




FIG. 2

3/25

Stimulation of neurite outgrowth by the C3-peptide.





FIG. 3

4/25

NCAM-Ig1 binding sequences identified from a combinatorial library of synthetic peptides.


<b>A</b>	<p> A R A L N W G A K P K  A G S A V K L K K K A  A K Y A L I P I R I S  A S T K R S M Q G I -  A R R A I L M Q M - A L  A Y Y L I V R V N R I  A T N K K T G R R P R  A K R N G P I I N R I  A K R S V Q K L D G Q  A R Q K T M K P R R S  A G D Y N P D L D R -  A S K K P K R N I K A  A R K T R E R K S K D  A S Q A K R R K G P R  A P K L D R M L T K K  A K K E K P N K P N D  A Q M G R Q S I D R N  A E G G K K K K M R A  A K K E R Q R K D T Q  A K K K E Q K Q R N A  A K S R K G N S S L M  A R K S R D M T A I K </p>
<b>B</b>	<p> C3 A S K K P K R N I K A  A K R N G P I I N R I  A K R S V Q K L D G Q  A S T K R S M Q G I -  A T N K K T G R R P R  A R A L N W G A K P K  A R Q K T M K P R R S </p>
<b>C</b>	<p> D3 A K K E R Q R K D T Q  A K K E K P N K P N D  A R K T K S R E R K D </p>
<b>D</b>	<p> D4 A R A L N W G A K P K  A T N K K T G R R P R </p>

FIG. 4

5/25

Inhibition of cell aggregation by the C3-peptide.


FIG. 5



6/25

C3-peptide promotes the formation of neuronal processes in primary cell cultures.

FIG. 6





7/25

Effect of NCAM-Ig1 binding peptides on cell aggregation and neurite outgrowth.

# Controls for NCAM Ig1 binding peptide (C3)

Peptide	Sequence										Effect*	
											Neur	agg
C3	A	S	K	K	P	K	R	N	I	A	++	-
C3-acetyl. K (120)	A	S	K	K	P	K	R	N	I	A	+	-
Ala subet K/R												
116	A	S	K	K	P	K	A	N	I	A	++	0
117	A	S	K	K	P	A	A	N	I	A	0	0
118	A	S	K	K	P	A	A	N	I	A	0	0
119	A	S	K	K	P	A	A	N	I	A	0	0
P->A												
122	A	S	K	K	A	K	R	N	I	A	++	-
Scrambled C3												
121	A	K	K	K	K	R	I	S	A	P	++	-
114	P	N	A	S	I	R	K	K	K	A	++	-
C3-α	K	N	A	S	K	R	R	K	K	K	++	-
D3	A	K	K	K	R	Q	R	K	D	Q	++	-
scrambled D3	R	T	K	K	D	K	R	K	E	K	++	-
D4	A	R	A	K	N	W	A	A	K	K	++	-
Scrambled D4	G	L	K	R	P	A	P	N	K	A	++	-
Poly-K												
K6 (dendrimer.115)	K	K	K	K	K	K	K	K	K	K	+	-


\* effect on neurite extension (neur) and aggregation (agg)  
# acetylation on lysine

FIG. 7

8/25

Effect of the C3-peptide on neurite outgrowth induced by NCAM-NCAM binding in cocultures of neurons and fibroblasts.


FIG. 8



9/25

Effect of the D3- and D4-peptides on neurite outgrowth in primary hippocampal cell cultures.


FIG. 9



10/25

Effect of C3-peptide on neurite outgrowth.


FIG. 10



11/25

Effect of C3 and control peptides on neurite outgrowth.


FIG. 11



12/25

Effect of signal transduction inhibitors on C3-stimulated neurite outgrowth.

FIG. 12




SUBSTITUTE SHEET (RULE 26)

13/25

Effect of signal transduction inhibitors on C3-stimulated neurite outgrowth.


Fig. 13



14/25

Effect of the recombinant NCAM Ig2 domain on neurite out-growth in primary hippocampal cell cultures.

Fig. 14






15/25

Effect of NCAM Ig2 and C3 on neurite outgrowth.


FIG. 15



16/25

Effect of the C3-peptide on proliferation of primary hippocampal cells.

FIG. 16



17/25


The predicted amino acid sequence of human NCAM-140.

1 MLQTKDLIWT LFFLGTAVAL QVDIVPSQGE ISVGESKEFL CQVAGDAKDK DISWFSNPGE  
61 KLTPNQQRIS VVWDDSSST LTIYNANIDD AGIYKCVVVG EDGSESEATV NVKIFQKLMF  
121 KNAPTQOEPR EGEDAVIVCD VVSSLEPTII WRHKGRDVIL KKDVRFIVLS NNYLQIRGIK  
181 KTDEGTYRCE GRILARGEIN FKDIQIVNV PPTIQARQNI VNATANLGQS VTLVCDAEFG  
241 PEPTMSWTKD GEQIEQEEDD EKIYPSDDSS QLTIKKVDKN DEAEYICIAE NKAGEQDATI  
301 HLKVFAPKPKI TYVENQTAME LEEQVTLTCE ASGDIPIPSIT WRTSTRNISS EEEKTLDGEMV  
361 VRSHARVSSL TLKSIQYTDG GEYICTASNT IGQDSQSMYL EVQYAPKLQG PVAVYTWEGN  
421 QVNITCEVFA YPSATISWFR DGQLLPSSNY SNIKIYNTPS ASYLEVTPDS ENDFGNYNCT  
481 AVNRIGQESL EFILVQADTP SSPSIDQVEP YSSTAQVQFD EPEATGGVPI LKYKAEWRAV  
541 GEEVWHKWKY DAKESMEGI VTIVGLKPET TYAVRLAALN GKGLGEISAA SEFKTQPVQG  
601 EPSAPKLEGQ MGEDGNSIKV NLIKQDDGGS PIRHYLVYR ALSSENKPEI RLPSSGDHVM  
661 LKSLDWNAEY EVYVVAENQQ GKSKAAHFVF RTSBQPTAIP ANGSPTSGLS TGAIVGILLV  
721 IFVILLVVVD ITCYFLNKG LFMCLAVNLC GKAGPGAKGK DMEEGKAAPS KDESKEPIVE  
781 VRTEERTPN HDGKHTTEPN ETTPLTEPEK GPVEAKPECO ETETKPAPAE VKTVPNDATQ  
841 TKNESKA

FIG. 17

18/25



The structure of the NCAM Ig1 and Ig2 domains when binding in a dimer.



19/25

The effect of the NCAM Ig2 domain and the Ig2-p peptide and control peptides derived from the Ig2-p peptide on cell aggregation.


Fig. 19



20/25

The effect of the Ig2-p peptide dendrimer on neurite outgrowth.


Fig. 20



21/25


Effect of the NCAM Ig2 domain and the Ig2-p peptide and control peptides derived from the Ig2-p peptide on neurite outgrowth.

Fig. 21



22/25

Micrograph showing the effect of the Ig2-p peptide on neurite outgrowth.






23/25

Effect of signal transduction inhibitors on neurite outgrowth stimulated by the Ig2-p peptide.


Fig. 23



24/25

Effect of the Ig1-p peptide on neurite outgrowth.


Fig. 24



25/25

Effect of mutations in the combined NCAM Ig1-Ig2 domain on neurite outgrowth.

Fig. 25



## CLAIMS

- 1 A compound which binds to the NCAM Ig1-Ig2 domains  
and is capable of stimulating or promoting neurite  
5 outgrowth from NCAM presenting cells and/or  
proliferation hereof.
- 2 A compound according to claim 1 which binds to the  
NCAM Ig1 domain.  
10
- 3 A compound according to claim 1 which binds to the  
NCAM Ig2 domain.
- 4 A compound according to claim 1 or 2 which binds to  
15 the homophilic binding site of the Ig1-Ig2 domains  
which is constituted by the Ig1 domain.
- 5 A compound according to claim 1 or 3 which binds to  
the homophilic binding site of the Ig1-Ig2 domains  
20 which is constituted by the Ig2 domain.
- 6 A compound according to any of the claims 1, 2 or 4  
which compound is the NCAM Ig2 polypeptide or a  
fragment or a mimic hereof.  
25
- 7 A compound according to claim 6 which compound is the  
NCAM Ig2 polypeptide.
- 8 A compound according to claim 6 which compound is a  
30 fragment or a mimic of the NCAM Ig2 polypeptide.
- 9 A compound according to claim 1, 3 or 5 which  
compound is the NCAM Ig1 polypeptide or a fragment or  
a mimic hereof.  
35

- 10 A compound according to claim 9 which compound is the NCAM Ig1 polypeptide.
11. A compound according to claim 9 which compound is a  
5 fragment or a mimic of the NCAM Ig1 polypeptide.
12. A compound of any of claims 6-8 which compound is a peptide which binds to the NCAM Ig1 domain through a binding motif which comprises at least 2 basic amino  
10 acid residues.
13. A peptide of claim 12 which comprises at least 2 basic amino acid residues within a sequence of 10 amino acid residues.
- 15 14. A peptide of claim 13 which comprises at least 2 basic amino acid residues within a sequence of 3 amino acid residues.
- 20 15. A peptide of any of claims 6-8 or 12-14, characterised in that it comprises the sequence:
- $$(Xaa^+)_{m} - (Xaa)_{p} - (Xaa^+) - (Xaa^1)_{r} - (Xaa^+) - (Xaa)_{q} - (Xaa^+)_{n} ,$$
- 25 wherein Xaa<sup>+</sup> is a basic amino acid residue,  
Xaa<sup>1</sup> is any amino acid residue,  
Xaa is any amino acid residue, and  
m,n,p,q and r independently are 0 or 1.
- 30 16. A peptide according to any of claims 12-15 wherein the basic amino acid residues are lysine (K) or arginine (R).
- 35 17. A peptide according to any of claims 12-16 wherein r is 1.

18. A peptide according to claim 17 wherein Xaa<sup>1</sup> is proline (P) or glutamic acid (E).
19. A peptide according to any of claims 12-18 wherein at  
5 least one of m and n is 1.
20. A peptide according to claims 12-19 wherein the peptide comprises the sequence (K/R)<sub>0-1</sub>-K/R-X-K/R), wherein X has the meaning Xaa<sup>1</sup>, suitably the sequence  
10 K/R-K/R-X-K/R or K/R-X-K/R, more suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-E-K/R or K/R-K/R-E-K/R, even more suitably the sequence K-P-K, K-K-P-K, K-K-E-K or K-K-E-R and most suitably the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-  
15 E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
21. A peptide according to claim 20 which peptide has the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-  
20 E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
22. A peptide according to any of claims 12-21 wherein one or more of the amino acid residues is modified,  
25 such as being acetylated.
23. A peptide according to any of the claims 12-22, which peptide is identical to a part of the NCAM Ig2 domain.  
30
24. A peptide according to any of the claims 12-22, which peptide is a mimic of the NCAM Ig2 domain or of a fragment of the NCAM Ig2 domain.  
35

25. A peptide according to any of claims 12-24, which peptide binds to the NCAM Ig2 binding site on the NCAM Ig1 domain.
- 5 26. A peptide according to any of claims 12-24, which peptide binds to a binding site on the NCAM Ig1 domain, which binding site is different from the NCAM Ig2 binding site.
- 10 27. A compound according to any of the claims 6-8, which compound is a non-peptide molecule mimicking binding to the Ig1 domain of the NCAM Ig2 domain or a fragment thereof or a peptide mimic thereof.
- 15 28. A compound according to any of the claims 6-8, which compound is an anti-NCAM Ig1 antibody.
29. An antibody according to claim 28, which antibody is monoclonal.
- 20 30. An antibody according to any of claims 28-29, which antibody is chimeric or humanised.
- 25 31. A compound according to any of the claims 2 and 4 which compound is a peptide, where the binding motif comprises at least 2 basic amino acid residues and at least 1 apolar amino acid.
- 30 32. A peptide according to claim 31 where the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.
- 35 33. A peptide according to any of the claims 31 and 32 where the number of amino acid residues in the sequence of the binding motif is within 8 amino acid residues.

34 A peptide of any of the claims 2,4,31,32 and 33,  
characterised in that it comprises the sequence:  
(Xaa<sup>+</sup>) - (Xaa) - (Xaa) - (Xaa)<sub>m</sub> - (Xaa<sup>+</sup>) - (Xaa) - (Xaa<sup>-</sup>)<sub>n</sub> - (Xaa<sup>h</sup>) -  
5 (Xaa)<sub>o</sub> - (Xaa<sup>h</sup>)<sub>p</sub>,

wherein Xaa<sup>+</sup> is a basic amino acid residue, Xaa<sup>-</sup> is a  
an acidic amino acid residue, Xaa<sup>h</sup> is a apolar amino  
acid residue, Xaa is any amino acid residue, and  
10 m,n,o and p independently are 0 or 1.

35 A peptide according to any of the claims 31-34,  
wherein the basic amino acid residues preferably are  
lysine (K) or arginine (R).

15 36 A peptide according to any of the claims 31-34,  
wherein the the acidic amino acids preferably are  
glutamic acid (E) or aspartic acid (D), the apolar  
amino acids are preferably leucine (L), isoleucine  
20 (I), valine (V) or phenylalanine (F), and r  
preferably is 1.

37 A peptide according to claims 31-36 wherein the  
peptide comprises the sequence (K/R)-X-X-X-(K/R)-X-  
25 (E/D)-(L/I/V/F)-X-(L/I/V/F), wherein X is any amino  
acid residue, suitably the sequence (K/R)-X-(E/D)-  
(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(E/D),  
(K/R)-X-X-(K/R)-X-(E/D) or (K/R)-X-(L/I/V/F)-X-  
(L/I/V/F), more suitably the sequences (K/R)-X-X-X-  
30 (K/R)-X-(E/D)-(L/I/V/F), (K/R)-X-X-(K/R)-X-(E/D)-  
(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(L/I/V/F), even more  
suitably the sequences (K/R)-X-X-(K/R)-X-(E/D)-  
(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(L/I/V/F)-  
X-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F)-  
35 (L/I/V/F) and most suitably the sequence GRILARGEINFK  
(SEQ ID NO: 23).



- 38 A peptide according to claims 37 wherein the peptide has the sequence GRILARGEINFK (SEQ ID NO:23).
- 5 39. A peptide according to any of claims 31-38 wherein one or more of the amino acid residues is modified, such as being acetylated.
- 10 40. A peptide according to any of the claims 31-39, which peptide is a mimic of, is a fragment of or is identical to a part of the homophilic binding site of the NCAM Ig1-Ig2 domains which is constituted by the Ig2 domain.
- 15 41. A non-peptide according to any of the claims 2 and 4.
42. A compound according to claims 4, which compound is an antibody against the Ig1 domain.
- 20 43. An antibody according to claim 42, which antibody is monoclonal.
44. An antibody according to any of claims 42-43, which antibody is chimeric or humanised.
- 25 45. A compound according to any of the claims 3 and 5 which compound is a peptide, where the binding motif comprises at least 2 acidic amino acid residues and at least 1 apolar amino acid.
- 30 46. A peptide according to claim 45 where the the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.

35

47 A peptide according to claim 46 where the number of amino acid residues in the sequence of the binding motif is within 9 amino acid residues.

5 48 A peptide according to any of the claims 3, 5, 45, 46 and 47, characterised in that it comprises the sequence:

10  $(\text{Xaa}^-) - (\text{Xaa}) - (\text{Xaa}) - (\text{Xaa})_m - (\text{Xaa}^+)_n - (\text{Xaa}^-) - (\text{Xaa}^-) - (\text{Xaa}^h) - (\text{Xaa}^h)_p,$

wherein  $\text{Xaa}^+$  is a basic amino acid residue,  $\text{Xaa}^-$  is an acidic amino acid residue,  $\text{Xaa}^h$  is a apolar amino acid residue,  $\text{Xaa}$  is any amino acid residue, and  
15  $m, n, o$  and  $p$  independently are 0 or 1.

49 A peptide according to any of the claims 45-48, wherein the basic amino acid residues preferably are lysine (K) or arginine (R).  
20

50 A peptide according to any of the claims 45-48, wherein the the acidic amino acids preferably are glutamic acid (E) or aspartic acid (D), the apolar amino acids are preferably leucine (L), isoleucine (I), valine (V) or phenylalanine (F), and  $r$  preferably is 1.  
25

51 A peptide according to claims 45-50 wherein the peptide comprises the sequence  $(\text{E/D}) - \text{X} - \text{X} - \text{X} - (\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F}) - \text{X} - (\text{L/I/V/F})$ , wherein X is any amino acid residue, suitably the sequence  $(\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F}) - \text{X} - (\text{L/I/V/F})$ ,  $(\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F}) - (\text{L/I/V/F})$ ,  $(\text{E/D}) - \text{X} - \text{X} - \text{X} - \text{X} - (\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F})$ ,  $(\text{E/D}) - \text{X} - \text{X} - \text{X} - (\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F})$  or  $(\text{E/D}) - \text{X} - \text{X} - (\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F})$ , more suitably  $\text{E/D}) - \text{X} - \text{X} - (\text{E/D}) - \text{X} - (\text{K/R}) - (\text{L/I/V/F}) - \text{X} - (\text{L/I/V/F})$  or  $(\text{E/D}) - \text{X} - \text{X} -$   
30  
35

(E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F), even more suitably  
the sequences  
(E/D) -X-X-X-X- (E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F),  
(E/D-X-X-X- (E/D) -X- (K/R) - (L/I/V/F) -X- (L/I/V/F) or  
5 (E/D) -X-X-X- (E/D) -X- (K/R) - (L/I/V/F) - (L/I/V/F), and  
most suitably the sequence GEJSVGESKFFL (SEQ ID NO:  
26).

52 A peptide according to claims 51 wherein the peptide  
10 has the sequence GEJSVGESKFFL (SEQ ID NO: 26).

53. A peptide according to any of claims 45-52 wherein  
one or more of the amino acid residues is modified,  
such as being acetylated.

15

54. A peptide according to any of the claims 45-53, which  
peptide is a mimic of a part of the homophilic  
binding site of the NCAM Ig1-Ig2 domains which is  
constituted by the Ig1 domain.

20

55. A non-peptide according to any of the claims 3 and 5.

56. A compound according to any of the claims 3 and 5,  
which compound is an antibody against the Ig2 domain.

25

57. An antibody according to claim 56, which antibody is  
monoclonal.

58. An antibody according to any of claims 56-57, which  
30 antibody is chimeric or humanised.

59. A compound according to any of the claims 1-58 or a  
fragment hereof or a mimic hereof for use in a  
treatment of normal, degenerated or damaged NCAM  
35 presenting cells.

60. A compound according to any of the claims claims 1-58, for use in a treatment, which consists of stimulation of outgrowth from and/or proliferation of the NCAM presenting cells.
- 5
61. A compound according to any of the claims 1-60 for use in a treatment according to any of the claims 59-60 wherein the treatment is a treatment of diseases and conditions of the central and peripheral nervous
- 10 system, of the muscles or of various organs.
62. A compound according to any of the claims 1-61 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases or conditions of
- 15 the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct
- 20 dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia.
- 25 63. A compound according to any of the claims 1-62 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases of muscles including conditions with impaired function of neuro-muscular connections such as genetic or traumatic
- 30 atrophic muscle disorders.
64. A compound according to any of the claims 1-62 for use in a treatment according to claim 61 wherein the treatment is a treatment of diseases of various
- 35 organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus

type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

- 5 65. A compound according to any of the claims 1-62 for use in a treatment according to any of the claims 59-60 wherein the treatment is a stimulation of ability to learn and/or of the memory.
- 10 66. Use of a compound according to any of the claims 1-58 in the manufacture of a medicament for the treatment of normal, degenerated or damaged NCAM presenting cells.
- 15 67. Use according to claim 66 wherein the treatment is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.
- 20 68. Use according to any of claims 66-67 wherein the medicament is for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct
- 25 dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or conditions of the muscles including conditions with
- 30 impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus
- 35 type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

69. Use according to any of claims 66-67 wherein the medicament is for the stimulation of the ability to learn and/or of the memory.
- 5
70. A pharmaceutical composition comprising one or more of the compounds according to any of the claims 1-58.
71. A composition according to claim 70 wherein the  
10 compound is the NCAM Ig1 peptide or a fragment or a mimic thereof.
72. A composition according to claim 70 wherein the  
15 compound is the NCAM Ig2 peptide or a fragment or a mimic thereof.
73. A composition according to any of the claims 70-72 wherein the peptides are formulated as multimers.
- 20 74. A composition according to any of the claims 70-73, characterised in that the peptides are formulated as dendrimers, such as four peptides linked to a lysine backbone, or coupled to a protein carrier such as BSA.
- 25
75. A method of treating normal, degenerated or damaged NCAM presenting cells *in vitro* or *in vivo*, characterised in that an effective amount of one or more of the peptides according to any of the claims  
30 1-58 or a pharmaceutical composition according to any of the claims 70-74 is administered *in vitro* or *in vivo*.
76. A method according to claim 75 wherein the treatment  
35 is a stimulation of neurite outgrowth from and/or proliferation of NCAM presenting cells.

- 5 77. A method of any of claims 75-76 wherein the treatment is an *in vivo* treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or of diseases or conditions of the organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.
- 10 78. A method according to any of claims 75-76 wherein the treatment leads to regeneration of nerves.
- 15 79. A method according to claim 78 wherein the compounds are used in combination with a prosthetic device.
- 20 80. A method according to claim 79 wherein the device is a prosthetic nerve guide.
- 25 81. A prosthetic nerve guide, characterised in that it comprises one or more of the compounds according to any of the claims 1-81 or a composition according to any of the claims 71-74.
- 30 82. Method of stimulating the ability to learn and/or the memory in a subject, characterised in that an
- 35

effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 71-74 is administered to said subject.

5

83. Medicament for the treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs, characterised in that the medicament comprises an effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 70-74 and one or more pharmaceutically acceptable additives or carriers.

10 84. A medicament according to claim 83 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.

15 85. A pharmaceutical composition for use in the stimulation of learning and/or memory in a subject, characterised in that the composition comprises an effective amount of one or more of the compounds according to any of the claims 1-58 or a composition according to any of the claims 70-74 and one or more pharmaceutically acceptable additives or carriers.

20 86. A composition according to claim 85 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00500

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 7/08, C07K 14/78, A61K 38/39, A61P 25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REG, CAPLUS, WPI, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5840689 A (JOANNE K. DANILOFF), 24 November 1998 (24.11.98) --	1-86
P,X	Biochem. J., Volume 340, 1999, Ken-ichiro et al, "An IKLLI-containing peptide derived from the laminin alpha1 chain mediating heparin-binding, cell adhesion, neurite outgrowth and proliferation, represents a binding site for integrin alpha3beta1 and ....", page 119 - page 126, see LA5 or LA5L --	45-51
A	WO 9409808 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA), 11 May 1994 (11.05.94), see seq 10 --	12-21

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

27 March 2000

Date of mailing of the international search report

03-04-2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf / EÖ

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00500

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	W09632959 A1 (ACORDA THERAPEUTICS), 24 October 1996 (24.10.96), see claims4-5  -----	1-86

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/DK99/00500**

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **75-80, 82-84**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 99/00500

Claims 75-80, 82-84 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/12/99

International application No.

PCT/DK 99/00500

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5840689 A	24/11/98	NONE	
WO 9409808 A1	11/05/94	AU 2895192 A US 3653080 A	24/05/94 04/04/72
WO 632959 A1	24/10/96	NONE	

# PCT

## NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

HØIBERG APS  
Nørre Farimagsgade 37  
DK-1364 københavn K  
DANEMARK

Date of mailing (day/month/year) 25 April 2001 (25.04.01)	
Applicant's or agent's file reference P9585PC00	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/DK99/00500	International filing date (day/month/year) 23 September 1999 (23.09.99)
International publication date (day/month/year) 06 April 2000 (06.04.00)	Priority date (day/month/year) 29 September 1998 (29.09.98)
Applicant RØNN, Lars, Christian, B. et al	

- The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
- An **asterisk(\*)** appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- The **letters "NR"** appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
29 Sept 1998 (29.09.98)	PA 1998 01232	DK	13 Octo 1999 (13.10.99)
29 Apr 1999 (29.04.99)	PA 1999 00592	DK	13 Octo 1999 (13.10.99)

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

Jean-Marie McAdams

Telephone No. (41-22) 338.83.38

## PCT

### NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HØIBERG APS  
Nørre Farimagsgade 37  
DK1364 København K  
DANEMARK

Date of mailing (day/month/year)  
10 July 2000 (10.07.00)

Applicant's or agent's file reference  
P9585PC00

International application No.  
PCT/DK99/00500

### IMPORTANT NOTIFICATION

International filing date (day/month/year)  
23 September 1999 (23.09.99)

1. The following indications appeared on record concerning:

☐ the applicant

☐ the inventor

☒ the agent

☐ the common representative

Name and Address

PATRADE AS  
Aaboulvarden 21  
DK-8000 Aarhus C  
Denmark

State of Nationality

State of Residence

Telephone No.

+45 7020 3770

Facsimile No.

+45 7020 3771

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person

☒ the name

☒ the address

☐ the nationality

☐ the residence

Name and Address

HØIBERG APS  
Nørre Farimagsgade 37  
DK-1364 København K  
Denmark

State of Nationality

State of Residence

Telephone No.

+45 3332 0337

Facsimile No.

+45 3332 0384

Teleprinter No.

3. Further observations, if necessary:

**Please note that a power of attorney for the new agent is needed.**

4. A copy of this notification has been sent to:

☒ the receiving Office

☐ the International Searching Authority

☒ the International Preliminary Examining Authority

☐ the designated Offices concerned

☒ the elected Offices concerned

☐ other:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

N. Lindner

Telephone No.: (41-22) 338.83.38

003400010

From the INTERNATIONAL BUREAU

**PCT****NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 25 May 2000 (25.05.00)	
<b>International application No.</b> PCT/DK99/00500	<b>Applicant's or agent's file reference</b> P9585PC00
<b>International filing date</b> (day/month/year) 23 September 1999 (23.09.99)	<b>Priority date</b> (day/month/year) 29 September 1998 (29.09.98)
<b>Applicant</b> RØNN, Lars, Christian, B. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

26 April 2000 (26.04.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).



<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer C. Villet
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P9585PC00		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/DK99/00500	International filing date (day/month/year) 23/09/1999	Priority date (day/month/year) 29/09/1998	
International Patent Classification (IPC) or national classification and IPC C07K14/78			
Applicant RONN, LARS CHRISTIAN et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 8 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"><li>I <input checked="" type="checkbox"/> Basis of the report</li><li>II <input type="checkbox"/> Priority</li><li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li><li>IV <input type="checkbox"/> Lack of unity of invention</li><li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li><li>VI <input type="checkbox"/> Certain documents cited</li><li>VII <input type="checkbox"/> Certain defects in the international application</li><li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li></ul>			
Date of submission of the demand 26/04/2000		Date of completion of this report 07.02.01	
Name and mailing address of the international preliminary examining authority.  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Schwachtgen, J-L Telephone No. +49 89 2399 8933 	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/DK99/00500

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

**Description, pages:**

1-79 as originally filed

**Claims, No.:**

1-55 with telefax of 29/01/2001

**Drawings, sheets:**

1/25-25/25 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/DK99/00500

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims 1-55
	No: Claims
Inventive step (IS)	Yes: Claims 1-55
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-32, 35-37, 42-50, 53
	No: Claims

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/DK99/00500

**Re Item I**

**Basis of the report**

The amendments filed with the fax dated 29/01/2001 meet the requirements of Article 34(2)(b) PCT.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. The subject-matter of amended claim 1 of the present application relates to a compound comprising an amino acid sequence having at the most 12 amino acid residues from the sequence of NCAM, said compound comprising the sequence (K/X)0-1-K/R-X-K/R, wherein said compound is capable of binding to the NCAM Ig1-Ig2 domains and stimulating neurite outgrowth.

None of the prior art documents disclose the subject-matter of claim 1, either alone or in combination. Claim 1, thus, meets the requirements of Article 33(2) and (3) PCT.

The same applies to claims 2-55.

2. Claims 33, 34, 38-41, 51 and 52 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Re Item VIII**

**Certain observations on the international application**

Claims 40, 54 and 55 are not supported by the description as required by Article 6 PCT, as their scope is broader than justified by the description and drawings. The

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/DK99/00500

application does not contain sufficient technical support for the use of compounds according to claim 1 in the treatment of "diseases of various organs".

## Claims

- 1 A compound comprising an amino acid sequence having at the most 12 amino  
acid residues from the amino acid sequence of neural cell adhesion molecule  
5 (NCAM), or a mimic thereof comprising an amino acid sequence having at the  
most 12 amino acid residues, said compound comprising
- the sequence  $(K/R)_{0-1}-K/R-X-K/R$ , wherein X is any amino acid, and/or
- 10 the sequence  $(K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F)-X-(L/I/V/F)$ , wherein X is any  
amino acid residue, and/or
- the sequence selected from the group  $(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F)$ ,  
 $(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F)$ ,  $(E/D)-X-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)$ ,  $(E/D)-$   
15  $X-X-X-(E/D)-X-(K/R)-(L/I/V/F)$  or  $(E/D)-X-X-(E/D)-X-(K/R)-(L/I/V/F)$ ,
- said compound being capable of binding to the NCAM Ig1-Ig2 domains and of  
stimulating or promoting neurite outgrowth from NCAM presenting cells and/or  
proliferation hereof.
- 20
- 2 The compound according to claim 1, capable of binding to the NCAM Ig1 do-  
main.
- 3 The compound according to the claims 1 or 2, capable of binding to the ho-  
mophilic binding site of the Ig1-Ig2 domains which is constituted by the Ig1  
25 domain.
- 4 The compound according to any of the claims 1, 2 or 3, wherein said com-  
pound is a fragment of the NCAM Ig2 polypeptide.
- 30
- 5 The compound of claim 4, capable of binding to the NCAM Ig1 domain  
through a binding motif which comprises at least 2 basic amino acid residues.
- 6 The compound of claim 5 comprising at least 2 basic amino acid residues  
35 within a sequence of 10 amino acid residues.

- 7 The compound of claim 6, comprising at least 2 basic amino acid residues within a sequence of 3 amino acid residues.
- 5 8 The compound according to the claims 8-12, comprising the sequence K/R-K/R-X-K/R or K/R-X-K/R, wherein X is any amino acid, more suitably the sequence K/R-P-K/R, K/R-K/R-P-K/R, K/R-K/R-E-K/R or K/R-K/R-E-K/R, even more suitably the sequence K-P-K, K-K-P-K, K-K-E-K or K-K-E-R and most suitably the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
- 10 9 The compound according to claim 1, having the sequence A-S-K-K-P-K-R-N-I-K-A (SEQ ID NO:1), A-K-K-E-R-Q-R-K-D-T-Q (SEQ ID NO:2), or A-R-A-L-N-W-G-A-K-P-K (SEQ ID NO:3).
- 15 10 The compound according to any of claims 5-9, wherein one or more of the amino acid residues is modified, such as being acetylated.
- 20 11 The compound according to any of the claims 5-10, being identical to a part of the NCAM Ig2 domain.
- 12 The compound according to any of the claims 5-10, being a fragment of the NCAM Ig2 domain.
- 25 13 The compound according to any of claims 5-12, capable of binding to the NCAM Ig2 binding site on the NCAM Ig1 domain.
- 14 The compound according to any of claims 5-12, capable of binding to a binding site on the NCAM Ig1 domain, wherein the binding site is different from the NCAM Ig2 binding site.
- 30 15 The compound according to claim 14, wherein the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.
- 35 16 The compound according to any of the claims 14 and 15, wherein the number

of amino acid residues in the sequence of the binding motif is within 8 amino acid residues.

- 5 17 The compound according to the claims 12-16, wherein the peptide comprises the sequence (K/R)-X-(E/D)-(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(E/D), (K/R)-X-X-(K/R)-X-(E/D) or (K/R)-X-(L/I/V/F)-X-(L/I/V/F), wherein X is any amino acid residue, more suitably the sequences (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F), (K/R)-X-X-(K/R)-X-(E/D)-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(L/I/V/F), even more suitably the sequences (K/R)-X-X-(K/R)-X-(E/D)-(L/I/V/F)-X-(L/I/V/F), (K/R)-X-X-X-(K/R)-X-(L/I/V/F)-X-(L/I/V/F) or (K/R)-X-X-X-(K/R)-X-(E/D)-(L/I/V/F)-(L/I/V/F) and most suitably the sequence GRILARGEINFK (SEQ ID NO: 23).
- 10 18 The compound according to claim 17, having the sequence GRILARGEINFK (SEQ ID NO:23).
- 15 19 The compound according to any of the claims 12-18, wherein one or more of the amino acid residues is modified, such as being acetylated.
- 20 20 The compound according to any of the claims 12-19, being a fragment of, or is identical to a part of the homophilic binding site of the NCAM Ig1-Ig2 domain which is constituted by the Ig2 domain.
- 25 21 The compound according to claim 1, capable of binding to the NCAM Ig2 domain.
- 30 22 The compound according to the claims 1 or 32, capable of binding to the homophilic binding site of the Ig1-Ig2 domains which is constituted by the Ig2 domain.
- 35 23 The compound according to any of the claims 1, 32 or 33, wherein said compound is a fragment of the NCAM Ig1 polypeptide.
- 24 The compound according to any of the claims 21 and 23 being a peptide, wherein the binding motif comprises at least 2 acidic amino acid residues and at least 1 apolar amino acid.



- 25 The compound according to claim 24, wherein the number of amino acid residues in the sequence of the binding motif is within 12 amino acid residues.
- 5 26 The compound according to claim 27, wherein the number of amino acid residues in the sequence of the binding motif is within 9 amino acid residues.
- 27 The compound according to the claims 21-26, wherein the peptide comprises the sequence (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F), wherein X is any amino acid residue, more suitably E/D)-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F) or (E/D)-X-X-(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), even more suitably the sequences (E/D)-X-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-X-(L/I/V/F) or (E/D)-X-X-X-(E/D)-X-(K/R)-(L/I/V/F)-(L/I/V/F), and most suitably the sequence GEJSVGESKFFL (SEQ ID NO: 26).
- 10 28 The compound according to claim 27, wherein the peptide has the sequence GEJSVGESKFFL (SEQ ID NO: 26).
- 15 29 The compound according to any of the claims 22-28, wherein one or more of the amino acid residues is modified, such as being acetylated.
- 20 30 The compound according to any of the claims 23-29, being a part of the homophilic binding site of the NCAM Ig1-Ig2 domains which is constituted by the Ig1 domain.
- 25 31 The compound according to any of the claims 1-30, wherein a fragment thereof is for the use as a medicament.
- 30 32 The compound according to claim 31, wherein a fragment thereof is for the manufacture of a medicament for treatment of normal, degenerated or damaged NCAM presenting cells.
- 35 33 Use of a compound comprising at the most 12 amino acid residues from the amino acid sequence of neural cell adhesion molecule (NCAM), or a fragment thereof, or a mimic thereof as defined in any of claims 1-32, capable of binding

to the NCAM Ig1-Ig2 domains and of stimulating or promoting neurite outgrowth from NCAM presenting cells and/or proliferation hereof.

5      34      The use according to claim 33, wherein said compound are for the use as a medicament.

35      The use according to claim 34, wherein said compound are for the manufacture of a medicament for treatment of normal, degenerated or damaged NCAM presenting cells.

10

36      The use according to claim 34, for the manufacture of a medicament for treatment comprising the stimulation of outgrowth from and/or proliferation of N-CAM presenting cells.

15      37      The use according to claim 34, for the manufacture of a medicament comprising treatment of diseases and conditions of the central and peripheral nervous system, of the muscles or of various organs.

20      38      The use according to claim 34, comprising treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, post-ischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia.

25

39      The use according to claim 34, comprising treatment of diseases of muscles, including conditions with impaired function of neuro-muscular connections such as genetic or traumatic atrophic muscle disorders.

30      40      The use according to claim 34, comprising treatment of diseases of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

35      41      The use according to claim 34, comprising stimulation of the ability to learn

and/or of the memory.

- 42 A pharmaceutical composition, comprising one or more of the compounds according to any of the claims 1-32.
- 5
- 43 The pharmaceutical composition according to claim 42, wherein the compound is a fragment of the NCAM Ig1 peptide.
- 44 The pharmaceutical composition according to claim 42, wherein the compound is a fragment of the NCAM Ig2 peptide.
- 10
- 45 The pharmaceutical composition according to any of the claims 42-44, wherein the compounds are formulated as multimers.
- 15
- 46 The pharmaceutical composition according to any of the claims 42-44, characterised in that the compounds are formulated as dendrimers, such as four peptides linked to a lysine backbone, or coupled to a protein carrier such as BSA.
- 20
- 47 The pharmaceutical composition according to any of the claims 42-46 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonal administration.
- 25
- 48 The pharmaceutical composition according to any of the claims 42-47, characterised in that the pharmaceutical composition comprises an effective amount of one or more of the compounds according to any of the claims 1-32, or a pharmaceutical composition according to any of the claims 42-47 and one or more pharmaceutically acceptable additives or carriers.
- 30
- 49 The pharmaceutical composition according to the claims 42-47 for use in the stimulation of learning and/or memory in a subject, characterised in that the composition comprises an effective amount of one or more of the compounds according to any of the claims 1-32 or a pharmaceutical composition according to any of the claims 42-47 and one or more pharmaceutically acceptable additives or carriers.
- 35

50 The pharmaceutical composition according to claim 49 formulated for oral, percutaneous, intramuscular, intracranial, intraventricular, intranasal or pulmonary administration.

5

51 Use of a pharmaceutical composition as defined in claim 50, wherein the composition is in combination with a prosthetic device.

52 The use according to claim 51, wherein the device is a prosthetic nerve guide.

10

53 A prosthetic nerve guide, characterised in that it comprises one or more of the compounds according to any of the claims 1-32, or a pharmaceutical composition according to any of the claims 42-47.

15

54 Use according to claim 34, wherein said compound is an NCAM Ig1 fragment for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia; for treatment of diseases or conditions of the muscles including conditions with impaired function of neuromuscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

20

25

30

55 Use according to claim 34, wherein said compound is an NCAM Ig2 fragment for treatment of diseases or conditions of the central and peripheral nervous system, such as postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic, e.g. resulting from a stroke, Parkinsons disease, Alzheimers disease, dementias such as multiinfarct dementia, sclerosis, nerve degeneration associated with diabetes mellitus, disorders affecting the circadian clock or neuro-muscular transmission, and schizophrenia.

35

phrenia; for treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, such as genetic or traumatic atrophic muscle disorders; or for treatment of diseases or conditions of various organs, such as degenerative conditions of the gonads, of the pancreas such as diabetes mellitus type I and II, of the kidney such as nephrosis and of the heart, liver and bowel.

10

15